Podcasts about nih

In his weekly clinical update, Daniel Griffin and Vincent Racaniello are angered by the continuous reporting of measles deaths in the US and around the world, the Ebola outbreak in Uganda, changes in reporting of virus infection and vaccine recommendations, establishing an NIH research center on vaccine harms, Legionnaires at Yankee stadium and the first time in more than half a century reporting of an equine screwworm case, and how HHS may prevent more than half of US children from getting the COVID-19 vaccine this season before Dr. Griffin deep dives into recent statistics RSV, influenza, SARS-CoV-2 infections, efficacy and safety of the 2026-2027 COVID-19 vaccine, and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode   Unvaccinated Woman Likely Died of Measles Complications, Pa. County Coroner Says NY Times) Confirmed death of an 18-year old due to complications of measles (Facebook: Mifflin County Coroner's Office) CDC's new tracking method for measles deaths puzzles experts (CIDRAP) Kennedy to deliver keynote for anti-vaccine group he once led (STATNews) Exclusive: New NIH research center on vaccine harms takes shape (Science) US pediatricians report seeing fewer patients because of immigration enforcement worries (CIDRAP) Surgeon General Nominee Pledges Support for Vaccines in Senate Hearing (NY Times) CIDRAP Op-Ed: HHS is asking what to call vaccine recommendations. You have 4 days to weigh in. (CIDRAP) 21,000 Unvaccinated Children Are Not a Minor Problem, But a Warning Sign (GPEI) Researchers file First Amendment challenge to NIH grant screening (Science) Cooling towers at Yankee Stadium test positive for Legionnaires' in new cluster (NBC News) Legionnaires' Disease (NYC: Health) Dashboard SCREWWORM.Gov (USDA: Animal and Plant Health Inspection Service) CDC Activates Emergency Operations Center for New World Screwworm Response (CDC Newroom) Texas ranch horse becomes nation's first confirmed equine New World screwworm case (Houston Chronicle) Quick takes: Cautious optimism on Ebola, rare New World screwworm in a horse, HIV alert in Fiji (CIDRAP) Ebola dashboard (ebola.fyi) EBOLA: The Democratic Republic of the Congo, 2026 (WHO) Bundibugyo virus disease outbreak Democratic Republic of the Congo (WHO: Democratic Republic of Congo) Ebola Outbreak: Current Situation (CDC:Ebola) Notes from the Field: The First 100 Days of Five Ebola Outbreaks — Democratic Republic of the Congo, Uganda, and West Africa, 2007–2026  (CDC: MMWR) Notes from the Field: Characteristics and Monitoring of the 2026 Outbreak of Ebola Disease Caused by Bundibugyo Virus — Democratic Republic of the Congo, August 2026 (CDC:MMWR) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Big outbreak, bright lights…Measles Dashboard (South Carolina Department of Public Health) Utah measles outbreak response (Utah Department of Health and Human Services) Utah Measles Dashboard (Utah Department of Health and Human Services) Measles (VDH: Virginia Department of Health) Tracking Measles Cases in the U.S. (Johns Hopkins) HAP's Latest News Pa. Launches New Measles Dashboard (Hospital + HealthSystem Association of Pennsylvania) Measles (Commonwealth of Pennsylvania) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Measles (CDC: Measles Rubeola) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Measles in Bangladesh (microbeTV: TWIV) Suspected measles cases kill nearly 1,000 as Bangladesh struggles to contain outbreak (AP News) Measles Cases and Outbreaks (CDC: Rubeola) Laboratory Testing for Measles (CDC: Measles (Rubeola) Measles Clinical Diagnosis Fact Sheet (CDC: Measles (Rubeola) Measles Serology Testing (CDC: Measles (Rubeola) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Flu vaccine recommendations: Vaccines and Related Biological Products Advisory Committee March 12, 2026 Meeting Announcement (FDA) WHO updates all 3 viral strains to be included in fall flu shots (CIDRAP) FDA vaccine advisers recommend adding subclade K to fall shots (CIDRAP) Weekly surveillance report: clift notes (CDC FluView) OPTION 2: XOFLUZA $50 Cash Pay Option (xofluza) Early Antiviral Therapy in Pediatric Outpatients and Risk of Influenza-Related Hospitalization (Pediatrics) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) RSV Immunization Effectiveness and Safety for the 2026-2027 Respiratory Season (JAMA) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines (Moderna) Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season (novavax) Pfizer and BioNTech Receive U.S. FDA Approval for XFG-adapted COVID-19 Vaccine (Pfizer) FDA approves new COVID vaccines (CIDRAP) Covid Vaccines Delayed for Half of U.S. Children (NY Times) COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season (JAMA) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID Reaching out to US house representative Letters read on TWiV 1358 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks!   Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Canada's Carney addresses the European parliament, a U.N. mission finds "reasonable ground" to believe the U.S. committed war crimes in its Iran strikes, the Philippines' Duterte appears in person before the International Criminal Court, Sweden's Kristersson resigns following his bloc's election defeat, King Charles hosts an AI summit in Scotland, reports allege that OpenAI pays contractors to read and rate users' chats, a group of scientists sue the NIH over its grant keyword screening, Fiji declares HIV a national crisis, a study finds that Greenland and Antarctica lost 11.3 trillion metric tons of ice between 1979 and 2023, and a new wild cat species is found in Bolivia's cloud forest. Sources: Verity.News

久しぶりのお便り回。ビッグラボでのサバイバル、神経＆免疫、メリトクラシー等々、たくさんのお便りありがとうございます。今後も感想・コメントお待ちしております（特典音源あり）。 (2026/09/11 収録)Show Notes (番組HP):お便りフォーム 。完全匿名希望（メールアドレス記入したくない）の方は、マシュマロからどうぞ。Masa Inoue (NR出演回 #35, #65)免疫の昔読んだ論文(RABIDseq)とその解説NR回(#11) アストロとミクログリアでした(萩)カレルのブログあみぐだらGut-brain論文生理研大学院たまきんが博士課程の学生に1000万をと言った: 政治家は旗振るのが仕事とは言ったが、この人に関してはお前大蔵省出身だろというツッコミが成立するのか、と収録後に思った（藤）安宅さんのブログ記事メリトクラシー回 (#107)NIHに1ドルいれると2.57ドルになるという試算 ”For every $1 invested in NIH research, there was $2.57 generated in economic activity — a 250% return”マスク論文: 単著ではなくMusk and Neuralinkでした（藤）利根川先生坂野先生インタビュー長井さん (NR出演回: #97, #98)憧れるのをやめましょう森先生小坂田さん回 (#104)山本渉さん回 (#108)小豆島は香川県でした。香川県民の皆様ほんとうに申し訳ありません！（藤）←日本の大学院行ってないからこうなっちゃうんじゃないの？(萩話が脱線して言いそびれましたが、夜光虫（#108に出てくるbioluminescent）が日本、しかも岡山でも見られるとは初知りでした！Shotaroさん、ありがとうございます。（藤）ベネッセアートサイト直島Art Basel森下さん五十嵐さん(NR出演回: #23, #24, #25, #26, #76, #100)がChairをしているGRCSpring Hippocampal Research ConferencePNW vowel mergerに関してはこの動画がわかりやすい ←エッグが通じなかったのはただ僕の発音が悪かっただけな気が笑（藤）元論文1, 2カッパのロゴ: æ ←この発音記号のことを言いたかった汗（藤） Editorial Notes:藤島氏の野球ネタが誰にも通じないのツボなのでやり続けて欲しい(次回への伏線です) (萩) 黒子のバスケかと思いました (脇) 空振り三振までまだ一回チャンス残ってる。ツーストライクからのホームラン打ちます。(藤) 

“I don't need to track it. I just listen to my body,” says Ezekiel J. Emanuel, M.D., Ph.D., Ms.C.  Dr. Emanuel is an oncologist and world leader in health policy and bioethics. He is the Vice Provost for Global Initiatives at the University of Pennsylvania, and holds appointments in the Department of Medical Ethics and Health Policy in the Perelman School of Medicine and the Department of Health Care Management in the Wharton School. He is Special Advisor to the Director General of the WHO, Senior Fellow at the Center for American Progress, and a member of the Council on Foreign Relations. He was founding chair of the Department of Bioethics at the NIH. He served as a Special Advisor on Health Policy to the Director of the Office of Management and Budget and National Economic Council. In this role, he was instrumental in drafting the Affordable Care Act. He served on the Biden-Harris Transition Covid Advisory Board. Dr. Emanuel is the most widely cited bioethicist in history with over 350 publications. He has authored or edited 16 books. His newest book, Eat Your Ice Cream, is out now.  00:00 - When tracking our health goes overboard 06:19 - The health markers worth testing 08:03 - Daily nutrition habits 09:34 - What it means to “eat your ice cream” 14:15 - The importance of social connection 19:12 - Why willpower fails & habits win 24:47 - Everest, introverts, & grip strength 27:52 - How purpose is linked to health 31:06 - Why & how the Emanuel brothers succeeded  35:21 - Rethinking retirement for brain health 36:42 - Age-old health wins (& that's a relief) 40:10 - Favorite ice cream shops Referenced in the episode:  For more about Emanuel, visit his website: https://www.ezekielemanuel.com/  Buy Eat Your Ice Cream here: https://www.amazon.com/Eat-Your-Ice-Cream-Healthy/dp/1324117532/ref=as_li_qf_sp_asin_il_tl?tag=mind0a3-20  Find our episode on the rabbit cholesterol here: https://youtu.be/er3k40nlCh8?si=MxeG7IxEVnirxIoX We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Episode 383 | Smart Meters, Informed Consent, and the Right to Opt OutCecelia “Cece” Doucette, director of Massachusetts for Safe Technology, joins us to make the case for a meaningful right to opt out of wireless “smart” utility meters. Cece explains how smart meters differ from older analog and digital meters, why their constant two-way radiofrequency transmissions raise health and informed-consent concerns, and what advocates are doing to secure an opt-out without punitive fees. A regular guest on CHD.TV, Cece is also a public educator and legislative advocate who has taken the stage at the last two Children's Health Defense national conferences. Through Massachusetts for Safe Technology, she offers no-cost monthly webinars, practical safer-tech guidance, legislative education, and resources citizens can use in their own communities. I met Cece this spring at the National Health Federation Conference in Dallas. We look at the case for consumer choice, what an opt-out should actually look like, the political obstacles advocates face, and what Washington residents can learn from efforts underway in Massachusetts and elsewhere. Massachusetts for Safe Technology: https://www.ma4safetech.org/Facebook: https://www.facebook.com/MA4SafeTech/LinkedIn: Cecelia Doucette: https://www.linkedin.com/in/cecelia-doucette-09655155/Events and free webinars: https://www.ma4safetech.org/eventsSafer Screentime: https://www.saferscreentime.org/Understanding EMFs: https://sites.google.com/site/understandingemfs/Health in Buildings Roundtable Conference at NIH: https://www.youtube.com/playlist?list=PLMAz9ZRXjYmp8vCf4HKxmLhdqEgbqYS65Generation Zapped, award-winning film: https://www.youtube.com/watch?v=5p4vRB5uU0A You can support Informed Life Radio by always starting your Amazon shopping at the link on our homepage, InformedChoiceWA.org. This gives us a small commission at no extra cost to you.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Poul Thorsen, the researcher behind vaccine-autism studies cited for years to shut down debate, is now facing fraud charges. Dr. Robert Malone joins Del to break down the scandal and what it means for the public's trust in vaccine science.Then, Jefferey Jaxen follows the road to the mRNA rollout, from Fauci's NIH inner circle and Moderna's rise to new research examining lipid nanoparticles, immune disruption, and cancer progression. Plus, Sen. Ron Johnson reports on Canada's Allison Inquiry, where witnesses are sharing accounts of injuries they say followed COVID-19 vaccination.And, Del sits down in the studio with Kim Rogers, known to millions as “The Worm Queen,” to discuss parasites, cleansing, and her own health journey. Finally, COVID hero Dr. David Brownstein joins the show to discuss his upcoming Vaccine and Immunology Conference.Guests: Dr. Robert Malone, M.D., M.S., Sen. Ron Johnson, Kim Rogers, David Brownstein, M.D.Airdate: September 10, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

The drugs in your medicine cabinet were probably discovered on your dime, in a university lab, with NIH money. You don't hold the patent. You don't set the price. Same story with the touchscreen, the GPS and the voice assistant in your pocket.The public often helps fund breakthroughs, while private companies claim all the profits. Economist Mariana Mazzucato thinks it's time to renegotiate. In “The Common Good Economy: A New Compass”, she makes the case for reshaping markets around the common good. Luigi Zingales and Bethany McLean press the uncomfortable question: can a government captured by business really be trusted to change the rules?You can find “The Common Good Economy: A New Compass” here: https://marianamazzucato.com/books/the-common-good-economy/the-common-good-economy-us/ Mariana Mazzucato is a Professor at University College London, Founding Director of the UCL Institute for Innovation and Public Purpose and author of “The Common Good Economy: A New Compass”.Connect with us:

Snoring may be a nuisance, but for some people it can be a sign of obstructive sleep apnea, a common condition that disrupts breathing during sleep and can have serious health consequences if left untreated.In this episode of Health Matters, host Courtney Allison speaks with Dr. Ana Krieger, director of the Center for Sleep Medicine at NewYork-Presbyterian and Weill Cornell Medicine, about what causes snoring, how sleep apnea develops, and why so many people unknowingly live with the condition.Dr. Krieger explains how sleep affects virtually every system in the body, from the brain and cardiovascular system to memory and cognitive function. She discusses common symptoms of sleep apnea, risk factors such as age, weight changes, alcohol use, and menopause, and the importance of testing when symptoms arise.The conversation also explores treatment options ranging from CPAP therapy and dental devices to newer treatment approaches, while offering practical advice for improving sleep hygiene and building habits that support better sleep and long-term health.Chapters00:00 – Snoring, Sleep Apnea, and What Causes ThemWhat happens in the airway during sleep, why people snore, and how sleep apnea develops04:00 – Symptoms and Warning Signs of Sleep ApneaCommon symptoms, hidden signs, risk factors, and why many people don't realize they have sleep apnea06:30 – How Sleep Affects the Brain and BodyThe role of sleep in memory, cognitive function, cardiovascular health, and overall well-being10:45 – Sleep Apnea Treatments and Better Sleep HabitsCPAP therapy, dental devices, newer treatment options, and practical tips for improving sleep hygieneKey Topics CoveredSnoringSleep apneaObstructive sleep apneaSleep disordersSleep studiesSleep testingSleep healthCognitive healthMemory and sleepBrain healthCardiovascular healthAtrial fibrillationSleep deprivationSleep qualityCPAP therapyMandibular advancement devicesSleep apnea treatmentsSleep hygieneInsomnia and stressMenopause and sleep apneaAlcohol and sleepHealthy sleep habitsBreathing during sleepSleep medicineKey TakeawaySnoring is often harmless, but it can also be a sign of sleep apnea, a common condition that affects breathing, sleep quality, and overall health. Recognizing symptoms early, seeking evaluation when needed, and prioritizing healthy sleep habits can help improve sleep, protect brain and heart health, and enhance quality of life.Doctor BioDr. Ana Krieger is director of the Center for Sleep Medicine at NewYork-Presbyterian/Weill Cornell Medical Center and Weill Cornell Medicine. She is a professor of clinical medicine in the Departments of Medicine, Neurology and Genetic Medicine and chief of the Sleep Neurology Division in the Department of Neurology at Weill Cornell Medicine. She is a board certified specialist in Sleep Medicine by the American Academy of Sleep Medicine.Dr. Krieger also holds board certifications in internal medicine and pulmonary medicine and has a master's degree in global public health with emphasis in healthcare policy and management. Over the past 25 years, Dr. Krieger has been actively involved in providing comprehensive patient care in sleep medicine, overseeing the Center for Sleep Medicine, a group practice that evaluates over 1,000 patients each month in New York City.She is also actively involved in medical and subspecialty education and research. As a clinician scientist, Dr. Krieger is the principal investigator in collaborative multidisciplinary research projects in sleep medicine and has published extensively in the field.Her current research is sponsored by the National Institutes of Health (NIH) and the National Science Foundation. She serves as Chair of the Mentored to Independence (MTI) K99/R00 grant review committee at the National Heart Lung and Blood Institute (NHLBI) at the NIH. Dr. Krieger is an active lecturer, regularly contributing to media efforts aiming at improving sleep health in the population. She is a Robert Wood Johnson Scholar, and Fellow of the New York Academy of Medicine, American College of Chest Physicians and American Academy of Sleep Medicine.

Dr. Doug takes a closer look at OsteoBoost and the research behind its claim to reduce bone loss, including the NIH-funded clinical trial, FDA clearance, and what the data actually shows for women with osteopenia and osteoporosis. He also compares targeted vibration to whole-body vibration, discusses using OsteoBoost alongside osteoporosis medications and hormone therapy, and explains who may benefit most from this device.*Previous Osteoboost videos on the Dr. Doug Show*https://youtu.be/zXldEexcWmYhttps://youtu.be/pdGGMERl6VAhttps://youtu.be/zt_0evLeOqQhttps://www.osteoboost.com/drdougUse promo code DRDOUG50 to save $50 on the osteoboost.

September 5, 2026The Trump administration had a busy Friday, US District Judge Talwani blocked Trump's illegal and unconstitutional plan to use the US Postal Service to screen mail-in voters, A day after Interior Secretary Burgum announced that work was starting on Trump's arch, US District Court Judge Chutkan ordered the administration to give the court notice before proceeding, Trump said the Iran War is not a war, and denied that military personnel are seeing record long deployments, and that the US controls the Strait of Hormuz, Trump also denies reports of a shortage of munitions, and Pete Hegseth is forcing members of the military's Joint Staff to take lie detector tests to prove they were not source of leaks, The Defense Department and NIH are moving funds for medical research to the Pentagon, where the Navy has run out of money, Trump appears to misunderstand how trade and trade deficits work, And the US was the only country to vote against a UN resolution to change the world map to more accurately reflect the size of continents, more than 450 years after the commonly used Mercator projection was created.Watch today's recording here: https://www.youtube.com/live/g9TUa1Rwd6U?si=T8_KKcHQZElhpnZ-Get full, free access to Letters from an American here: https://heathercoxrichardson.substack.com/subscribeYou can also find me:Bluesky: https://bsky.app/profile/hcrichardson.bsky.socialInstagram: https://www.instagram.com/heathercoxrichardson/?hl=enFacebook: https://www.facebook.com/heathercoxrichardson/YouTube: https://www.youtube.com/@heathercoxrichardson Get full access to Letters from an American at heathercoxrichardson.substack.com/subscribe

In this episode, Ray Cochrane breaks down Hot Chips 2026, the engineering conference where IBM, NVIDIA, Intel, AMD, Arm, and Fujitsu all showed how their next processors actually work. The headline disclosure is a mainframe core that runs Arm natively. Ray also covers Apple’s odd M6 Mac mini naming, London’s first autonomous Uber rides, Amazon’s purchase of the company behind DuckDB, GitHub’s HydraFusion, the best of IFA 2026, and new USDA research on farmed salmon. – Want to start a podcast? It’s easy to get started! Sign-up at Blubrry – Thinking of buying a Starlink? Use my link to support the show. Subscribe to the Newsletter. Email Ray if you want to get in touch! Like and Follow Geek News Central’s Facebook Page. Support my Show Sponsor: Best Godaddy Promo Codes Get 1Password Full Summary Cochrane opens the show with a personal update. He apologizes for the late rollout and the missed Monday episode, having spent the week fighting a cold. He’s also heading to Michigan to spend time with family and visit his father’s gravesite. He hopes to record a couple of shows from his dad’s old studio while he is there, including a special episode planned for Tuesday. He also points listeners to a fresh site redesign that trades the old techie look for something cleaner and friendlier. The featured segment starts from a wrap-up post on Arm’s newsroom. However, Cochrane broadens it to cover the whole conference rather than a single article. Hot Chips has run every August since 1989, and this year’s event was the 38th, held August 23rd through the 25th at Stanford’s Memorial Auditorium. What Hot Chips Actually Is Cochrane draws a line between Hot Chips and the big consumer trade shows. CES and Computex exist for product announcements and marketing. Meanwhile, Hot Chips is an IEEE engineering conference where chip architects present block diagrams and die photos for thirty minutes at a stretch. The audience matters as much as the content. Roughly five hundred people who design chips for a living fill the room, and they would spot a fudged number immediately. No written paper is required, just the talk and the slides. In-person tickets sold out this year, as did Stanford’s dorm housing. Cochrane says he plans to cover the conference annually going forward. IBM Built a Mainframe Core That Speaks Arm The disclosure that stopped Cochrane cold came from IBM. Its next processor for IBM Z and LinuxONE runs two completely different instruction sets natively, on every one of its eleven cores. Those are z/Architecture, IBM’s own mainframe language, and AArch64, which is 64-bit Arm. Crucially, this is not emulation. Nor is it Arm cores glued onto the die beside the mainframe cores. IBM built 2,792 Arm instructions directly into the hardware, which it says is more than double the mainframe instruction count. Each core carries two separate decoders while sharing the caches, branch predictor and register files downstream. It switches between the two in nanoseconds. IBM even added dedicated hardware to flip byte order, because Arm and the mainframe store numbers in opposite directions. The payoff is Arm SystemReady compliance, meaning off-the-shelf Arm Linux runs on a mainframe unmodified. Patrick Kennedy of ServeTheHome, who was in the room, wrote: “I am sitting here still in awe of what IBM is doing here; this is not Z plus Arm cores, this is Z and Arm in one core.” Cochrane flags one precision point that is easy to get backward. IBM did not license Arm’s core designs and drop them in. Instead, it took its own mainframe core and taught it AArch64 under an architecture license, which is considerably harder engineering. The specifications are striking. The chip uses a 2nm process, with eleven cores running above 5.7GHz sustained and no turbo mode at all. Each core gets 36MB of L2 cache, backed by a 3.5GB virtual L4 pool. Furthermore, the reliability target is eight nines, which works out to roughly three tenths of one second of unplanned downtime per year. IBM gave it no name and no ship date, though the press expects “Telum III” around 2028. Arm, Fujitsu and NVIDIA Show Their Hands Arm itself had plenty to discuss, starting with an unfortunate name. Its first chip in thirty-five years is called the AGI CPU, which is a product name rather than any claim about artificial general intelligence. For three and a half decades, Arm designed processor blueprints and licensed them out, collecting royalties without competing. That era is now over. The AGI CPU is Arm’s own silicon, co-designed with lead customer Meta, running up to 136 cores on TSMC’s 3nm process at 300 watts. Arm’s CEO says the company has more than $2 billion in customer demand across the next two fiscal years. Fujitsu brought the detail Cochrane called the coolest of the conference. Its MONAKA chip packs 144 Arm-based cores, but the trick is the cache. Rather than sitting alongside the cores and eating die area, the entire last-level cache lives on a separate 5nm die with the 2nm compute die stacked directly on top. It ships in 2027 in 350-watt and 500-watt versions. NVIDIA had more stage time than anyone, with six sessions. Its new Vera CPU carries 88 cores of NVIDIA’s own Olympus design, which marks a change: the previous Grace CPU used Arm’s off-the-shelf cores. Consequently, Arm’s win here is the instruction set, not the blueprint. The memory disclosure drew the most attention, with a fully loaded system reaching 1.5TB at 1.2TB/s while the whole memory subsystem draws just 30 to 40 watts. The Caveat on NVIDIA’s Benchmark Slides Cochrane pushes back on how NVIDIA presented its numbers. On the standard SPEC integer benchmark, Vera scored 925 against AMD’s 128-core EPYC score of 898, about three percent ahead. However, the slide NVIDIA showed normalizes that same result per physical core, which makes a three percent gap look enormous. NVIDIA defends the choice, arguing that per-core throughput matters when thousands of AI agents run at once. Cochrane grants that it is a fair argument to make. Even so, his verdict is blunt: it is a different number from the headline one, and presenting it that way is not the best look. Sponsor: GoDaddy Economy hosting $6.99/month, WordPress hosting $12.99/month, domains $11.99. Website builder trial available. Use codes at geeknewscentral.com/godaddy to support the show. Apple’s Newest Chip Landed in Its Cheapest Mac Last week’s episode covered the Mac Studio half of Apple’s August announcement. Tonight Cochrane takes the other half, the new Mac mini, and finds the numbering genuinely strange. The $899 base Mac mini gets the M6, which is Apple’s first 2nm chip and the newest process the company has shipped. It brings twelve CPU cores, twelve GPU cores, and 170GB/s of memory bandwidth. Apple also introduced a third CPU core class called super cores. So Apple’s most advanced chip sits in its cheapest desktop, while the M5 Pro, M5 Max and M5 Ultra above it all carry a lower number. It gets stranger. The M6 mini has Thunderbolt 4 while the pricier M5 Pro mini has Thunderbolt 5, and the memory ceiling runs backward too. Apple explains none of it across three announcement pages. Reading between the lines, Cochrane figures the M6 is the entry point of a new generation that shipped ahead of its larger siblings. London’s Robotaxis Started Carrying Passengers Arm’s monthly roundup covers everything outside the data center, and Wayve stood out. Transport for London granted the British self-driving company private hire vehicle licenses on August 5th, the same category a minicab needs. Then on September 3rd the service launched with Uber, marking the first autonomous rides ever offered to UK passengers. A small fleet of Ford Mustang Mach-Es covers anywhere in London except the airports, with a TfL-licensed safety driver still aboard. Over 140,000 Londoners signed up. The compute runs on NVIDIA’s Arm-based automotive platform, which is why Arm claims the win. Cochrane notes the pattern: once you set a standard nobody can move off, these wins keep arriving. Two more items round it out, both about squeezing AI onto phones. Google’s Pixel 11 shipped in August with the Tensor G6, and Google claims on-device AI runs up to 3.5x faster using 3.5x less energy. Those are Google’s own unbenchmarked figures. Separately, Graphcore’s research team worked with Arm to run an 11-billion-parameter vision model on phone-class processors by squeezing each parameter to 2.7 bits, taking the model from roughly 22GB down to 3.7GB. Intel Is Pitching AI Infrastructure From a Long Way Back Intel’s newsroom post previews the AI Infra Summit, running September 15th through 17th in Santa Clara. CEO Lip-Bu Tan takes a fireside chat on Tuesday morning, with three Intel sessions across the show. Cochrane unpacks two terms first. Physical AI means AI that acts in the real world through sensors and motors rather than living on a screen, and Intel takes it seriously enough to have renamed its PC division the Client Computing and Physical AI Group in May. Disaggregated inference splits the two phases of running a model: reading your prompt is compute-hungry, while writing the answer back is memory-hungry. The context is where this gets interesting. Intel’s revenue rose 25 percent last quarter, its fastest growth since 2011. Nevertheless, in AI accelerators the company barely registers next to NVIDIA. Gaudi has effectively been abandoned, to the point that Intel stopped maintaining its open-source driver, and AMD passed Intel in data center revenue last quarter. Tellingly, when Intel demoed disaggregated inference at Computex, NVIDIA GPUs handled one phase and SambaNova chips the other while Intel supplied the coordinating CPU. Crescent Island, Intel’s actual inference chip, does not sample until later this year, and Intel declined to publish its memory bandwidth. Amazon Bought the Company Behind DuckDB On August 26th, Amazon signed a deal to acquire DuckLabs, the Amsterdam company behind DuckDB. Cochrane spends time explaining what DuckDB is, since listeners outside the data world may never have encountered it. The problem it solves is familiar. Querying a large pile of data files traditionally meant either running a database server or spinning up a data warehouse with a cluster, a bill, and a loading pipeline. Both are heavy machinery for a question you wanted answered in ten seconds. DuckDB instead ships as a library rather than a server. You add it to your program like any other package, point it at your files, and write ordinary SQL directly against them. The data never moves. The usual comparison is SQLite, which is embedded in nearly every phone and browser on earth. Where SQLite excels at looking up one record, DuckDB rebuilds that embedded idea for chewing through millions of rows. It now sees roughly 62 million monthly downloads on Python’s package index alone, up from about 25 million last October. AWS says it is buying the company, not the project. DuckDB stays free and open source under the MIT license, held by a Dutch nonprofit foundation, and the founders join AWS while continuing to run technical direction from Amsterdam. Andy Warfield, a VP and distinguished engineer at AWS, described DuckDB as “the glibc of structured data: a lean, unglamorous, ubiquitous dependency that a great deal of software links against and almost nobody has to think about.” Cochrane sits with what that ownership means. He reaches for an analogy: imagine Daniel Stenberg selling curl. He doubts it would ever happen, but the concept alone is startling given how much infrastructure depends on it. His read is that AWS is betting DuckDB becomes as foundational as curl and SQLite already are. GitHub Has One AI Model Grade Another One’s Homework GitHub shipped Project HydraFusion into Copilot as a research preview. Instead of routing your request to a single model, it picks one of three approaches per request. Sometimes one model simply answers. Alternatively, a cheaper model drafts, and a quality gate decides whether to escalate. The interesting one is Critique. One model writes the code, a separate model from a different family reviews it read-only, and the original gets one pass to revise. Despite the name, nothing is fused here. There is no voting and no merging, just one model at a time with a gate deciding whether to spend more. GitHub explained the reasoning in an earlier post: “a model reviewing its own work is still bounded by its own training biases: the same training data and techniques, the same blind spots.” Research supports it. A team at NeurIPS in 2024 showed that models recognize their own writing and score it higher than human graders do. GitHub’s earlier number had a Claude Sonnet and GPT critic pairing closing about three-quarters of the gap between Sonnet and the larger Opus model. This mirrors a workflow Cochrane uses constantly and has described on a previous episode. He runs a cross-check review with a second model from a different company, and it routinely surfaces issues the first model missed. He explains that different training data, different engineers, and different reinforcement approaches build different internal biases about what counts as correct. Looking ahead, he expects more of these “Frankenstein patterns” where models from different training families work together. The Best of IFA 2026, and What You Can Actually Buy IFA opened to the public in Berlin for its 102nd year, with about 1,900 brands. Cochrane splits The Verge’s roundup in two, since much of what generates headlines at these shows never ships. Starting with real products, iRobot’s flagship Roomba Max 875 Combo runs $1,199 and ships in about two weeks. Its SealForce feature drops a hidden skirt from the chassis when it detects carpet, sealing against the fibers so suction concentrates instead of leaking out the sides. That reaches 35,000 pascals, iRobot’s strongest yet. A step-down model at $899 carries the same trick, though Cochrane balks at both prices. Anker’s Soundcore Sleep 4 Pro earbuds arrive in November at $349.99. The charging case carries its own round touchscreen, so you pick soundscapes, set alarms, and read sleep stats without your phone. Optical sensors read heart rate and variability from the ear canal, which beats the wrist for accuracy, and the case masks a snoring partner. Cochrane remains unconvinced about sleeping with earbuds in. Philips also has smart rope lights, the Hue Liane 360, on sale now. They glow evenly around the tube rather than showing individual LEDs. They also run $400 for three meters, which works out to about $130 per meter of rope light. As for concepts nobody can buy, iRobot showed a robot vacuum that carries a smaller robot vacuum on its back in a garage and lowers it to deploy. Lenovo brought a 14-inch laptop whose screen rolls out to 17 inches at the press of a button, which reviewers call the first rollable that feels close to shippable. Tecno showed a phone with essentially no border around the screen, and Acer had a Windows gaming handheld that swivels its screen up over a keyboard. Two themes ran through the show. Humanoid robots were the loudest thing on the floor, and IFA’s own CEO framed the event as being about robots that work rather than robots that demo. Meanwhile, AI stopped being its own product category and became an ingredient, showing up in refrigerators, treadmills, dishwashers, and motorized TV mounts. Farmed Salmon Isn’t the Omega-3 Machine It Used to Be USDA scientists measured farmed salmon and found considerably less of the good fat than the government’s own database claims. EPA and DHA are two fatty acids you get almost entirely from fish. Your body can build them from the plant version, but only in tiny amounts, so the NIH’s position is that eating them is the only practical way to raise your levels. Those fatty acids are structural pieces of every cell, with DHA concentrating in the brain and retina. That is why the federal dietary guidelines, issued jointly by USDA and Health and Human Services, recommend at least eight ounces of fish a week and steer you toward salmon. That amount is calibrated to deliver about 250 milligrams a day. Published in Frontiers in Nutrition last month, the study found EPA and DHA in farmed Atlantic salmon came in 54.7 percent lower than USDA’s own reference values, last updated in 2018. A three-ounce serving fell from roughly 1,670 milligrams to about 756. Consequently, two servings a week now fall about 14 percent short of the target. Plant-derived fats meanwhile rose two to three times over. The likely cause is feed. Salmon are carnivores, and farms once fed them oily little fish. There was never going to be enough of those as the industry scaled, so crops filled the gap: soy, canola, sunflower and linseed. Importantly, the study does not claim to have proven this and calls the feed shift a plausible explanation. Independent corroboration lends it credibility. Researchers at Stirling measured a similar halving in Scottish salmon between 2006 and 2015, and Norway’s marine institute saw it across thousands of samples. There is a land dimension too. Roughly half the world’s soy grows in South America, where rainforest gets cleared for feed. Matthew Hayek, who studies the environmental cost of protein at NYU, told Inside Climate News that “soy is a major, important protein and oil ingredient in fish farming.” Adding up two decades of soy across all fish farming, he puts the extra forest clearing at around the area of Nicaragua or Bangladesh. That figure covers all fish farming rather than salmon alone, and Hayek notes it is hard to attribute soy use to any single species. Cochrane closes with two caveats. First, the study measured only eight fish, bought around Maryland, DC and Virginia over six weeks in 2023, and nearly all sourced from Chile. That is not a national survey, and the authors say plainly the sample was not large enough to change government advice. Rather, it flags that a federal database value needs rechecking, which is what the paper set out to do. Second, on whether you should care, farmed salmon still beats beef, chicken and eggs by a mile, since those carry essentially zero EPA and DHA. What it loses is its crown among fatty fish, dropping to mid-pack behind herring, sardines and mackerel and roughly level with trout. The broader health case is also softer than the 2000s suggested. A review of 86 trials covering 162,000 people found supplements barely moved heart attacks or deaths, so eating fish and swallowing fish oil are not the same claim. No producer has responded to the findings, and USDA, whose own scientists ran the study, declined an interview and did not answer emailed questions. Cochrane wraps up with housekeeping and a note that he will be back on Labor Day. The post The Mainframe Learned to Speak Arm #1875 appeared first on Geek News Central.

Harris County shows how prevention can reduce police and jail pressure as the Pentagon seeks NIH funds and 33 House Democrats join Republicans on a bill punishing Israel boycotts.Subscribe to our Newsletter:https://politicsdoneright.com/newsletterPurchase our Books: As I See It: https://amzn.to/3XpvW5o How To Make AmericaUtopia: https://amzn.to/3VKVFnG It's Worth It: https://amzn.to/3VFByXP Lose Weight And BeFit Now: https://amzn.to/3xiQK3K Tribulations of anAfro-Latino Caribbean man: https://amzn.to/4c09rbE

Send us Fan MailAmerican healthcare still runs on fax machines, paper forms, and reimbursement models built for reactive sick care. Meanwhile, patients are connecting wearables to AI chatbots, ordering their own labs, and triaging themselves without ever seeing a physician.Dr. Daniel Kraft, Founder of Digital.Health and NextMed Health, joins host John Driscoll to discuss why the consumer is pulling healthcare into the future faster than institutions can follow, and what continuous, AI-powered, multimodal health monitoring could mean for the 500 million people who cannot get timely access to a primary care doctor today.

Dr. Andrew Holman is a rheumatologist and the CEO of Seattle-based Inmedix, which recently received FDA clearance for the first cloud-based heart rate variability (HRV) diagnostic platform. Dr. Holman shares how a “detective” mindset led him from early interests in orthopedics and cardiology into rheumatology, fibromyalgia research, and ultimately entrepreneurship. He explains how chronic stress, the autonomic nervous system, and conditions like sleep apnea and restless leg syndrome can influence cardiovascular risk and autoimmune disease outcomes, and why measuring stress biology with medical-grade precision matters. Dr. Holman also offers hard-earned advice for physician-innovators, reflects on pivotal study results, and shares what he hopes to be remembered for: never dismissing patients in distress.  Guest links: https://www.inmedix.com | https://www.linkedin.com/company/inmedix-inc Charity supported: Save the Children Interested in being a guest on the show or have feedback to share? Email us at theleadingdifference@velentium.com.  PRODUCTION CREDITS Host & Editor: Lindsey Dinneen Producer: Velentium Medical   EPISODE TRANSCRIPT Episode 088 - Andrew Holman [00:00:00] Lindsey Dinneen: Hi, I'm Lindsey and I'm talking with MedTech industry leaders on how they change lives for a better world. [00:00:09] Diane Bouis: The inventions and technologies are fascinating and so are the people who work with them. [00:00:15] Frank Jaskulke: There was a period of time where I realized, fundamentally, my job was to go hang out with really smart people that are saving lives and then do work that would help them save more lives. [00:00:28] Diane Bouis: I got into the business to save lives and it is incredibly motivating to work with people who are in that same business, saving or improving lives. [00:00:38] Duane Mancini: What better industry than where I get to wake up every day and just save people's lives. [00:00:42] Lindsey Dinneen: These are extraordinary people doing extraordinary work, and this is The Leading Difference. Hello, and welcome back to another episode of The Leading Difference podcast. I'm your host, Lindsey, and today I'm delighted to be welcoming as my guest Dr. Andrew Holman. Dr. Holman is a rheumatologist and the CEO of Inmedix, a Seattle-based medical diagnostics company that recently received FDA clearance for the first cloud-based heart rate variability diagnostic platform. He has 25 years of clinical experience with 16 peer-reviewed papers and clinical trials demonstrating that measuring stress biology with medical grade precision can improve success rates in autoimmune diseases. All right. Andrew, welcome to the show. I'm so glad you're here today. [00:01:30] Andrew Holman: Yes, happy to be here. Thank you for inviting me. [00:01:33] Lindsey Dinneen: Course, of course. Well, I would love, if you wouldn't mind starting out telling us a little bit about who you are, what your background is, and what led you to medtech. [00:01:44] Andrew Holman: Sure. Well, I'm a, a guy from Seattle, Washington. Grew up here, but trained everywhere else, became a rheumatologist. We study autoimmune diseases, lupus, rheumatoid arthritis. I also was very interested in fibromyalgia and pain. We're the immunologists of medicine. So, I started my practice, golly, a while ago. 1992, I finished my prac- my training, and I was the main rheumatologist at a large suburban hospital at the southern end of Seattle. So hometown, circle back to the hometown. I went into rheumatology because you have many choices when you do internal medicine. You can go be a specialist in many things. But I like the puzzles. The immunology has grown and it's a, it's a particularly sort of detective-oriented specialty. So, I didn't set out to be an entrepreneur. That came 25 years later. I was an in-the-trenches doc trying to help the person in front of me with these devastating diseases that are crippling diseases, usually of young women mostly. [00:02:45] Lindsey Dinneen: Yeah. Okay, and I'm sure there's, there's much more we're gonna dive into, but one thing that really stood out really fast was you, you kind of called yourself a detective, which I really love that term. And so I'm curious, is that something that you always thought you wanted to specialize in, in medicine, or was this, you know, detectiving to come later? Was this something that, you know, you ended up learning more about while in med school and thought, "Oh, this sounds really cool. I could put really two interesting passions together"? [00:03:19] Andrew Holman: Yeah, it was-- you know, things just sort of come into play sometime. For those who are not in medicine, they may not realize it takes about ten years to go to college, med school, re- internship, residency, fellowship, you know, and then you, then you finally get to go be a doctor, and you have to go learn how to be a doctor s- a little more. The patients teach you a lot more than people realize. So I was gonna be an orthopedist. I liked orthopedics. I liked architecture, bones, joints. I thought it was a lot of fun. I just had very little aptitude for what they do. I, I don't-- I, I'm not very g- a good carpenter. I just, you know, I didn't-- just wasn't gonna be a great orthopedist. So then I thought, "I really love cardiology." Rhythm disturbances, all kinds of things. In the 1980s, when I was in medical school , all the new stents and procedures and non- less invasive things than bypass surgery were all coming up. Joint valve replacement. You know, it's really exciting. But I never... and I never took a, a f- a course in rheumatology until I was actually an intern in internal medicine program in Denver, all set to be a cardiologist. And there were 12 of us in the, in the program per year, and s- five of us became rheumatologists because of this one doctor who took us out, a guy named Daryl McCarter. Prob- maybe people who know him, he's retired recently. He would bring us in the office, and we'd see every other patient with him because in between the patients, he would give us an X-ray, say, "I want you to look at this. There's a clue here. See if you can find it." Or, "I want you to look at this pathology slide," or something. "There's a secret, you know, to figure this one out." And I go, "Wow, this is really fun stuff." And once you figured it out, we weren't as good at treating it yet, but we were getting better. We were getting better. So it was the cutting edge and very fertile ground for discovery. So, rheumatologists are called the consult of last resort for a reason. There aren't very many of us. You've usually seen everybody else first, and by the time they-- you see us, we're pretty good at figuring out the rare diseases that are not in other people's board exam. But we're also pretty good at figuring out the common disease that presents in a very strange way, you know? And, and that's what our strength is. So we may... Everybody who sees us who gets diagnosed may not have a rheumatology answer, but we try to get them an answer. And now we're really in the golden age of rheumatology in the last 20 years of really making a difference for so many people. The downside, we don't make a difference for enough people, you know? We, we... That's the problem. So we've got these very motivated doctors out there, eager, and we just need, you know, more. And that's why I became an entrepreneur, because I learned more neurology than I was supposed to know and more sleep physiology than I was supposed to know. You just follow the breadcrumbs, you know? [00:06:17] Lindsey Dinneen: Yeah. Okay, so I know you didn't start out wanting to, or maybe even being interested in being an entrepreneur, but that is the path that you chose, and I would love to hear about that, the company, and what you're all doing. And then also would love to hear about your journey into deciding that this is the next right step for me. [00:06:38] Andrew Holman: Yeah. Well, thanks for asking it. It is a little unusual. So I was actually studying and trying to help patients with fibromyalgia about 30 years ago. And fibromyalgia patients terribly dismissed till they're all making this up. There's not 10 million people that can make anything up and be consistent. I mean, they all say the same thing. So I thought that was nonsense, and I was really thrown into the crowd of, you know, "You're, you're crazy too." And I go, "Well, I'm board certified in crazy." So I w- I was interested in it, and I was irritated that these people were dismissed. And I was around other doctors in Seattle who were similarly that way, which was very, very unusual. It's unusual to find people in the '90s who had an avid interest in that disorder. And so I started doing what rheumatologists are good at, incrementally advancing ideas and therapeutics very carefully, very cautiously. We do a lot of things off-label. When I was-- finished my fellowship in 1992, half the diseases on our board exam had no FDA-approved treatment. We had to do something, right? You couldn't just say, "Well, come back when there's a couple of articles in the New England Journal of Medicine." You, you can't do that, right? People are depending on you. So rheumatologists are particularly good at that, and that's not something most doctors want to do. Most doctors find that very uncomfortable. They're very, very careful people. And, and rheumatologists are careful too, but we take this mission seriously that we need to do something for you. So basically, I was looking at off-label ideas and work on fibromyalgia, and I'll share this with your audience. I was actually pulled up-- pulled in by some senior doctors who said, "We wanna talk with you." And I'd been there about three years as a new doctor. Oh, you know, seem to be doing a good job. Maybe they wanna pat me on the back or something. No, not that. It was actually an intervention, which I had never... I mean, I had no familiarity with what an intervention was. And they said, "Look, we like you. You're a great doc, but you're gonna ruin your reputation if you believe all these people, mostly women And you really need to not take it so seriously or write prescriptions for this c-- this and that." I said, "Well, thank you very much." That's polite. That's not what I was thinking. And I, I... But it prompted me to pull all the charts and say, "You know, I think I'm making some progress here with some ideas here, and let me see if I'm getting fooled and just seeing the people who get better to come back. Let me really honestly look at my performance." And so I pulled about 200 charts. It was my first abstract at the national meeting. And you know what? We were making progress. That had morphed into more progress, following the breadcrumbs, looking at neurology, looking at the autonomic nervous system. So that was about a five-year process. Y-you know, I didn't lose my reputation, obviously. I lecture around the world now. But it led to being very careful about getting clinical evidence if I had a hypothesis. And so we were using the office, and we actually finally did a double-blind prospective study where I bought all the drug myself, had it reformulated, little capsules that, you know, and, and worked with the FDA to get permission to do the study. And that study in fibromyalgia to this day has the highest response rate of any fibromyalgia study for pain that's ever been done. Now, we don't use that treatment anymore. It's 20 years later, we have other things to do. But it did prompt Pharmacia, got bought by Pfizer, I believe, and Boehringer Ingelheim, which co-marketed the drug I was using and reporting on, to pay me $10 million for the patents that I had filed, utility patents. I didn't own the drug. I didn't use it for Parkinson's disease, but I thought there was use in fibromyalgia. So before I told the world, I filed utility patents, and they wanted to exploit that discovery. So did two other pharmaceutical companies, and they had to pay for the privilege of doing it. So at 46, I retired. So I didn't intend to do that, but I do come from a family of lawyers and judges, and so the idea of having a utility patent on a n- a new innovative idea was not a foreign concept to me. [00:10:40] Lindsey Dinneen: Yeah. [00:10:41] Andrew Holman: That is something I teach all young doctors. [00:10:46] Lindsey Dinneen: That is awesome, and I, I was thinking, okay, this is a great segue because first of all, that's an incredible story. Secondly, I, I would be very curious to know exactly that, what is your advice for some of these incredible physicians, great ideas, that are potentially going to end up becoming an entrepreneur just because that's the path that, that is sort of presented to them? What is some of your advice for that? 'Cause that can't just be... you, you had the privilege at least of, of, of knowing and having some background in that, the legal aspects of IP protection and whatnot, but what are some of the things that you tell people? [00:11:22] Andrew Holman: Well, a couple things I would say and I have these conversations often 'cause I really like the younger people coming along. I say, first of all, don't define yourself as an ent- as being an entrepreneur. Make sure you have other things in your life that are more important to you. Now, the investors are not gonna like to hear that. They, they want you to live and die on your, on your company, right? But I'm saying, you know, you don't have to tell the VCs, but have other things that matter more in your life. You still gotta work really hard because you may, you may find that it's really a slog, and it's very long, and it's very hard. But, you know, make sure that, that, that what you-- though is important, your family, you know, your integrity the scientific problem at hand, the patients, you know, they're number one. Make sure we don't lose sight of all that, and do a few things. Go for a walk. Do something for yourself. Something. I do this twenty-four seven for the last 10 years, you know, every day 'cause I love doing it. It does wear you out, though. Even if you make-- even if you're successful with milestones, it does wear you out. But that's what I tell them. I say, "You know, make sure that you take care of yourself a little bit, too." It's kinda like a analogy. What do you do for a pregnant woman who has a, who has a, a lupus? Lupus is terribly dangerous for the fetus and for the mom. Though the worst thing you do to-- for the baby is not take care of the mom. Take care of mom, [00:12:44] Lindsey Dinneen: Mm-hmm. [00:12:45] Andrew Holman: then get the baby delivered. So, you know, everybody's talking about the baby, but take care of mom. That's the most important thing you do for that baby. So that's kinda what I would say. [00:12:54] Lindsey Dinneen: Yeah. Yeah, that's great. I appreciate that. Yeah, that, that makes a lot of sense too. We've been talking, actually it's been a, a bit of a theme too lately in some of the conversations that I've been having with folks, especially leaders, to talk about that identity component and, and be aware that your job isn't the only thing that defines you or needs to. There's a lot more to your life. There's a lot more to who you are. And so also, you know, our identities change over time and how you refer to yourself and th- those are, those are good things. That's growth, that's movement. So, being comfortable with who you are outside of your career. Yeah. [00:13:33] Andrew Holman: The other thing too is, you know, people used to joke 20 years ago that participation mem- medals were like a farce and what. That's the l- that's the last thing I would say to anybody. Give yourself a pat on the back for going out there trying to attack the castle, you know. Give yourself some credit there because a lot of people just wouldn't do it. My middle daughter was a hundred-meter hurdler at Boise State. She's a Division I athlete. There's a lot of sprinters out there that don't wanna get anywhere near that hurdle 'cause it really hurts when you hit it, right? And so half of that was not-- was being brave. So be brave, be brave, you know. My other daughter was a Division I athlete at Rice. She was a h- she was a volleyball player. Yeah. So, yeah. So I, I, I, I watch other people, see how they persevere and, you know, okay, gotta pick yourself up. Gotta go. Gotta get up this morning. Gotta go. [00:14:23] Lindsey Dinneen: That's right. That-- Yeah. [00:14:25] Andrew Holman: Then remember, people are depending on you, not just your investors. I take that so seriously. But the s- the people who have decided that they're gonna hook their wagon to you. [00:14:34] Lindsey Dinneen: Yeah. [00:14:35] Andrew Holman: You know, that's a lot of responsibility. [00:14:37] Lindsey Dinneen: It is. Yeah. [00:14:38] Andrew Holman: Give yourself a little credit that you're stepping up. [00:14:41] Lindsey Dinneen: Yes. Great advice. Yeah. Okay, so all right. So let's talk about your company now. So now you're an entrepreneur, in addition to obviously the rest of who, what makes you, you. But and I know that you're also a clinical professor, and I would love to hear about both of those things if you don't mind sharing. [00:14:59] Andrew Holman: Yeah, sure. So, technically I'm an associate clinical professor at the University of Washington. A, a lot of private docs do, and they participate in helping teach the y-young residents and fellows and so forth. So it's a joy to me. I, I think my job is a job of teaching. I'm constantly talk... I'm not-- I don't see patients anymore, although I do maintain my license in malpractice 'cause I get, I get contacted for the fibromyalgia work I did. So it's, my email's on the papers, right? So I, I don't wanna let that go. People need help. But basically, we're constantly teaching patients, you know. Now, we're listening, hopefully do better and better at that, but then I have to make a case. You know, I'd, the-- I'd like you to try this or that. Why do I wanna do that and so forth. We're constantly, you know... We don't-- It, it sounds too trite to call it selling something. We're not doing that. We're in there with you. We're collaborating. But I have to be, I have to have a reason and be persuasive and all that, so that, that academic teaching part's kind of fun. Now, sometimes I go into the lion's den. I will tell you, it's a little nerve-wracking to give rheumatology grand rounds at Harvard. Yeah, yeah, okay. You know, and the University of Washington, they're a little friendlier. It's my hometown. But Guy's Hospital in London and the Hospital for Special Surgeries, I... My first rheumatology grand rounds came at the HSS in 2009. I get there, I completely bomb. All these famous people are in the front row. I'm... They're, they're just not buying any of this thing we call immunoautonomics and how stress affects the immune system. I'm quoting the NIH. I'm doing everything I... I know how to do it, right? Pathology slides, I'm there. Then I find out the way they pick the speakers is the fellows get to find something interesting, and they pick the speakers, not the not the high mucky-mucks. So the only reason I was there is because the fellows, the young folks, thought, "This is an interesting topic. We'd like to hear more." And it turns out they were 15 years ahead of the rest of the world, because this is the most fascinating topic of how the immune system affects the autonomic nervous system affects the immune system, so it inflames it. [00:17:03] Lindsey Dinneen: Yeah. Oh my gosh. Actually, that is one thing I wanted to talk about, 'cause I, I noticed on your LinkedIn profile there was, you know, a reference to how much stress affects cardiovascular health maybe particularly chronic stress. And I would just love to hear more about that and, and maybe some ways... I know there's like, y- of course you always get your standard, "Here are some things that you could do to lower your stress." But, but from your perspective as a physician who's studied this, I'd love to hear more from you about, okay, how does this affect health, especially cardiovascular health, and then really what are some practical things that we can do? [00:17:39] Andrew Holman: Yeah, let me see what I can do. Now I wish I could fast-forward because we will have some magnificent things in the next five to 10 years based on what's being discovered now. But the bottom line is, stress and pain are awful things, but they have a purpose in the near term. So pain is good because it'll keep you from putting your hand back in the fire, right? Just don't do that again. But chronic pain is terrible and not productive. Stress is the same thing. You wanna get away from the lion. You, you, you need to perform. If your child needs you, whatever, you, you need to perform on it instant. But chronic stress is not productive. The problem with the stress response is it's controlled in the brain by the autonomic nervous system, which is called the ANS, and it's divided into two components, the sympathetic fight or flight, which we all know what that feels like. You know, ooh, scary. And the other is the parasympathetic, which is getting more talk now, which is the opposite, which is related to rest, restorative, sleep, recovery, growth hormone, all these things. And both of these systems are on simultaneously all the time, but they jockey for predominance depending on what the demands are around you, right? So turns out the sympathetic part has a significant negative impact on cardiovascular health, as you might expect, right? If you're driving your car at five thousand RPMs-- now, nobody has a stick shift anymore-- but if you're driving at five thousand RPMs, you're gonna wear down your engine, even if you go at the same speed as someone who has a two thousand RPMs, right? It, it's, it's what's going on inside the hood there is really important. So stress responses chronically do have measurable, tangible, well-published effects on cardiovascular mortality in long prospective studies. So if we had a magic something, we would do something to lower that epinephrine adrenaline response. Unless, of course, you're in the military, where someone's-- you need every heightened, m-- you know, response that you can get to survive. But for the rest of us, it's better that that system does not ramp up and activate. And we all have a different propensity to how powerful it is and how much it turns on, and also how poorly it turns off. So the stress response, we think of it like epinephrine, adrenaline. That's the easiest way to do it. So what you'd wanna do is to make sure this magnificent part of your brain that is your-- does all your housekeeping functions, this autonomic nervous system, the command and control center that you just wanna work, you don't wanna think about it, is not on a turbocharged, right? And there are people I take care of that they were just born that way. A lot of them, by the way. So things like all the wellness opportunities you can think of are, are targeted just to simply calm the autonomic nervous system. Tai chi, meditation, diet, exercise, all these things have been around for thousands of years because of that. That's what they do. And the practitioners will share that with you. I mean, the there are monks that can lower their heart rate, you know, to like, you know, what would seem lethal to the rest of us, right? That's the parasympathetic drive that lowers heart rate, lowers blood pressure. So those wellness opportunities are real. It will be important that you can manage whether the-- what you're doing is working or not. [00:21:04] Lindsey Dinneen: Mm-hmm. [00:21:04] Andrew Holman: Right? And that's where my company comes in. But the other is things like obstructive sleep apnea. You might think heavy guys... See, someone's gonna send me for a sleep study for sure, but they're not gonna send you. Big mistake, because it turns out that fifty-three percent of Japanese women with rheumatoid arthritis have unexpected obstructive sleep apnea. Oops. And, and we were just taught that we wouldn't even check those people. Well, turns out sleep apnea untreated is a major cardiovascular risk factor equal to cigarette smoking, according to the Sleep Heart Health Study in 2004. That's a big deal. And also, we learned in rheumatoid arthritis, getting back to my work, world, that patients with rheumatoid arthritis don't die from joint disease, they die from premature heart disease. They can also get cancers. So why is that? Well, there's been a lot of effort to try to figure that out in the last twenty-five years, and their risk factors for cardiovascular disease are not explained by the Framingham risk factor of hypertension, cholesterol, smoking, and all the things we, we look, see. But nobody looked at sleep apnea. [00:22:15] Lindsey Dinneen: Mm-hmm. [00:22:17] Andrew Holman: The other reason it's so relevant, though, is sleep apnea is a potent sympathetic arousal. It, it-- You struggle to breathe, right? You kind of obstruct. And what part of your brain tells you to breathe? Your autonomic nervous system. Breathe, right? And it stimulates this adrenaline response over and over and over, and it pounds your heart over the years, and it can lead to sudden death and arrhythmias. So there's a, there's a link there. Never miss sleep apnea. The other one is we found in our office and published about restless leg syndrome. You know, people tap their toes in the airport or they kick the covers around at night. It's pretty benign for most people, but it looks like it very well might be a sympathetic arousal, and there may be relevance there. The therapies for that may have relevance to what we're talking about. Again, very off-label. We're not talking about FDA-approved here. But it-- You ask what can you do? The other one that's coming is vagus nerve stimulation. That is FDA-approved now for rheumatoid arthritis, and they're going to other opportunities to, again, to, to increase the parasympathetic and to lower the sympathetic, right? So that background activity doesn't harm you. The autonomic nervous system may be the primary reason that two patients respond differently to the same treatment. What you bring to the table. It's no different than if I have two people coming to me for a back problem. One is five foot three and one is seven foot three. The way their spine is designed makes it a whole lot harder to treat the seven-foot back, right? I'm not surprising anybody here. So there are things that the patients can bring to the table that matter. Here's the irony. Ninety-seven percent of patients with rheumatoid arthritis in a survey in England said that stress affected their disease activity. It's no surprise to them. And sixty-five percent said they thought it predated getting the disease, that it actually contributed to getting it in the first place. And now there's evidence to suggest that may be true. [00:24:17] Lindsey Dinneen: Oh, boy. [00:24:19] Andrew Holman: So we can't miss sleep apnea just out there. We can't miss restless leg. We can't miss Ehlers-Danlos type three hypermobility type where people can... you can't see me here, but my fingers can bend backwards. But it's, it basically it's very, very common, and those people tend to have increased sympathetic activity naturally. [00:24:39] Lindsey Dinneen: Fascinating. [00:24:39] Andrew Holman: So yeah, so we're, we're waking up a little bit to some very important features here of individuals that may help us do better with the diseases they also come in. [00:24:50] Lindsey Dinneen: Yeah. Wow. [00:24:52] Andrew Holman: Sorry, long answer. Sorry, but there's a lot. [00:24:54] Lindsey Dinneen: No, that's great. I appreciate it, and yeah, well, then there you go. Managing stress is critical to, to your health. It's not just a nice to have, like yeah, yeah, kind of thing. Okay. Whew. [00:25:07] Andrew Holman: Good learning. [00:25:08] Lindsey Dinneen: Okay, awesome. Yeah, so, I'm curious... Okay, so, so again, I like, I like looking at guests' LinkedIn profiles and, and learning more about, you know, what makes you tick outside of your career as well, and I noticed some very fun things that you have listed. So we've got creative writing, horsemanship, golf, and vintage passenger rail cars. I feel like this warrants... [00:25:33] Andrew Holman: Yeah, it's called... Yeah, the American Association of Private Railcar Owners. Yeah. I get ribbed a lot for that, but they're a great bunch. There are about --I don't know if I know all the numbers now, but about 75 to 80 vintage cars from the '20s, '30s, '40s, '50s, who tag on the back of Amtrak, and Amtrak drags them around, and you can actually go rent them, stay in them, whatever. And they have a a annual meeting where they just get on a private train, and they go on tracks that you wouldn't go on naturally, like private rails in the, you know, middle of nowhere. So that's what they like to do. And it's just a lot of fun, especially the dome cars. [00:26:12] Lindsey Dinneen: Okay. That's so cool. [00:26:14] Andrew Holman: I've been a handful of times. I've got a lot of friends there. I don't own a car, but boy, I'd sure like to have one. [00:26:19] Lindsey Dinneen: Yeah. Okay. That is so cool. And then how about horsemanship? How did you... Have you been riding horses your whole life, or how did that come about? [00:26:29] Andrew Holman: So I went to a high school called Thatcher School in Ojai, California, where there are 50 in a class, and there was a requirement, this is over 100 years old, this school, that you had to have a horse. And they would say s- that something about the "outside of a horse is good for the inside of a boy," right? I was the last all-male class in 1977. Now young women get to go there too. It's of note that I have 15 people from Thatcher investing as family and friends in, Inmedix. So, th-they that, that's pretty special. But it's a boarding school. I was there for four years. My dad had gone there, so I'd heard of it. But I got a tremendous education. Th-there aren't a lot of prep schools on the West Coast, but there are some. And, and that's where I learned how to ride a horse like riding a bicycle. My sister is a thoroughbred horse trainer for 40 years. She's retired. She had three or four or five horses, a har-- not the fancy kind of stuff at the Derby. But they, you know, get up at 4:00 a.m. and ride, you know, that kind of... Tough life, but she loved horses. So yeah, I, I'm as, I'm more comfortable on a horse than I am around anything, probably. [00:27:34] Lindsey Dinneen: That's so cool. Okay. Well, this has been really fun to, to get to hear your incredible life story so far, and I'm excited to see where the company continues to advance medical technology. So, you know, I really appreciate everything you're doing. But I do want to ask, is there a moment that stands out to you along your career path so far where you just thought, "Wow, I am in the right industry at the right time"? [00:28:02] Andrew Holman: Yeah, I'd, I'd say there probably was. When we unblinded the prospective double-blind study that we did looking at this five-minute next generation heart rate variability, this HRV we got through the FDA last year. When we unblinded the study, and although that's not part of the FDA clearance, it was a very important moment for me because it showed that it predicted a year in advance who would respond to treatment of rheumatoid arthritis with ninety percent sensitivity, ninety-five percent specificity. So I wanna emphasize that is not what it's cleared for. It's cleared as an HRV tool that doctors can use at their discretion. But that study is what you asked me to answer. And when you unlock a study and you see the results, two things happen. One is we were happy that I was on the right track. That was nice. You know, positive study. Your hypothesis is valid. But it completely changed the view of immunology, [00:28:58] Lindsey Dinneen: Hmm. [00:28:59] Andrew Holman: Because we would have a test now that could measure the autonomic nervous system with exquisite precision. Nobody cared except me. About 10 years ago, we were waiting for better biologics, the things on TV, right? They asked, "Ask your doctor if it's good for you." Nobody realizes that they work about twenty-five percent of the time in terms of disease control. That's a big gap, but it looks like it's the brain that monitors inflammation. The inflammation the immune system is not firewalled against everything. The brain c-controls it, and it's not the endocrine so much with cortisol, it's the autonomic that works in milliseconds that, that epinephrine response. So that's a... You know, you're pretty nervous when you un-- when you-- someone tells you, "Okay, here is the results." [00:29:48] Lindsey Dinneen: Yeah. Wow. [00:29:50] Andrew Holman: And, and, and that was it. And then it turned out in 2015, the other moment was when I was going through the airport at Seattle and I saw the cover of of Scientific American, Bioelectric Medicine, Setpoint Medical's vagus nerve stimulation, hacking the the vagus nerve to fix the autonomic nervous system to reduce the burden of rheumatoid arthritis. I go, "Okay, now it's time." We had the patent on it. Okay. Ten years forward, we're where we are now. We're launching in June, and we have a software juggernaut here and a literally a vital sign. So, th-the doctors decide what to do with this, but we've put it in their hands, and it's paid for by insurance. So yeah. [00:30:34] Lindsey Dinneen: Amazing. Well, that's, that's so cool. Congratulations on that. That's fantastic. Okay, so to pivot the conversation a little bit just for fun, [00:30:43] Andrew Holman: Hmm? [00:30:43] Lindsey Dinneen: imagine that you were to be offered a million dollars to teach a master class on anything you want. What would you choose to teach? [00:30:53] Andrew Holman: Well, I, I learned that you've all had professors that didn't probably know as much as they should about a subject, but they thought it was just fun. I would probably stick with what I know. So I would do a master class on fibromyalgia because you can actually treat it. And there's published data, but it's very-- it's not widely known. We will be using Inmedix and autonomic testing to do research to validate and get that problem finally solved and put to bed. And then the other is this thing called immunoautonomics. It, the term-- I made up the term 15 years ago. It's in the medical literature. So that's what I would teach. Teach what I know. [00:31:27] Lindsey Dinneen: I love that. Okay, excellent. And how do you wish to be remembered after you leave this world? [00:31:34] Andrew Holman: Well, I, you know, it all come... I define myself by what the patients, how they do and what they say. It's not about five stars and all that, you know, you know, there's plenty of those. But it's, it's... I made a, a commitment if somebody says anything about me, I made a commitment when I was a rheumatologist with all these mostly young women upset, that I would never leave the room with them crying. Didn't matter how far behind I was, didn't matter. We went through a lot of Kleenex. There's a l- it's devastating to get these diseases when you're a young woman. And they can put that on my tombstone, not to dismiss people. We had a saying in the office, "It's gotta be something." You know? It's, it's always something. Drives me crazy when doctors will say, "Oh, that's nothing." Well, well, first of all, we know it's not nothing. It, it is always something, and there's something that defines your success, and there has to be things that define your failure. So let's figure out what the something is, but let's not argue that there's nothing there. So let's not dismiss people who are frightened and worried, and maybe they don't tell the story as clearly as we'd hope. But you know what? It's not, it's not their fault. They're in distress. It's amazing what people are like after you help them with their chronic pain. [00:32:45] Lindsey Dinneen: Yeah. Yeah. That is really cool and makes so much sense. Yeah. Thank you. Okay, and then final question: what is one thing that makes you smile every time you see or think about it? [00:32:59] Andrew Holman: It's making me smile right now. When I talk to the young fellows that are in their training and they're finishing up, so they've done three years or four years of medicine, three years of internal medicine after that, and then they do three or two, three, four years of rheumatology, and then they're gonna go out, I tell them how jealous I am of what they're gonna see. The, the last, the last 40 years we had these young men mostly coming in with terrible weight loss and immune systems, falling apart, and these strange tumors, and they're dying of, of infections like yeast and candida that, you know, everybody did fine with, and it was HIV, right? It had to be figured out. Now HIV is a chronic disease. It's like diabetes. We had so many people die in the '80s. Hepatitis C was... You'd have liver enzymes up, and it wasn't hepatitis A 'cause we could test for that, and it wasn't hepatitis B 'cause we could test for that. So we just called it non-A, non-B. Literally, that's what we called it. And then that got to be called hepatitis C, right? 'Cause it was too embarrassing to call it n- what it wasn't. And now hepatitis C is curable with antiviral agents in, like, three weeks. I mean... And then the biologics showed up. They're not perfect, but they were a big step. And then this immunoautonomics and, and understanding how pain and sleep and the autonomic nervous system work. I'm just really jealous of what those young clinicians are gonna get to see. [00:34:27] Lindsey Dinneen: Yeah. Yeah, that's really... Yeah, I can see why. But it sounds like you are, you know, keeping, keeping your what, what would they say? Like, toe in the water or something so that you're able to, to watch some of this as well and be a part of that next [00:34:40] Andrew Holman: I feel like I'm a ne- I feel like I'm neck deep and I'm just hoping I don't go down any lower. [00:34:47] Lindsey Dinneen: Fair enough. [00:34:48] Andrew Holman: 'Cause I have to find a way to pay for it. [00:34:50] Lindsey Dinneen: Oh, yeah, yeah, yeah. The details, you know. Yeah, yeah. [00:34:53] Andrew Holman: You got those details, yeah. [00:34:54] Lindsey Dinneen: Yeah. Oh my gosh. Well, this has been an incredible conversation. I really appreciate your time today and sharing your insights and, and stories and, yeah, I'm so excited to see the future of medicine, and I appreciate perspectives of, like yours, where you just, you share a lot of hope and optimism, and you're actively working to change lives for a better world. So, thank you. [00:35:16] Andrew Holman: Yeah, I, I irritate a lot of people with that optimism, but I'm sorry, it's just there. I can't fix it. [00:35:22] Lindsey Dinneen: Brilliant. Well, I love it. It makes my heart happy, so thank you so much again, and I hope you have the best rest of your day. [00:35:31] Andrew Holman: Thank you so much. Thanks for having me. [00:35:32] Lindsey Dinneen: Of course. [00:35:34] Dan Purvis: The Leading Difference is brought to you by Velentium Medical. Velentium Medical is a full service CDMO, serving medtech clients worldwide to securely design, manufacture, and test class two and class three medical devices. Velentium Medical's four units include research and development-- pairing electronic and mechanical design, embedded firmware, mobile app development, and cloud systems with the human factor studies and systems engineering necessary to streamline medical device regulatory approval; contract manufacturing-- building medical products at the prototype, clinical, and commercial levels in the US, as well as in low cost regions in 1345 certified and FDA registered Class VII clean rooms; cybersecurity-- generating the 12 cybersecurity design artifacts required for FDA submission; and automated test systems, assuring that every device produced is exactly the same as the device that was approved. Visit VelentiumMedical.com to explore how we can work together to change lives for a better world.

The federal government awards more than $1 trillion in grants every year—and businesses, researchers, engineers, teachers, and entrepreneurs can compete for this non-dilutive funding. In this video, I interview Dr. Nipun Chopra, a neuroscience professor, biotech founder, federal grant writer, and consultant who has helped companies win funding from the DoD, NIH, NSF, and ARPA-H. Nipun explains how his company won $10,000, $65,000, and $220,000 awards to develop and test an innovative technology for people with Parkinson's disease.He breaks down his top three recommendations for winning grants.Ready to start your government contract consulting business, career or company? Join over 400 others in the GovClose Professional Development Program: https://www.govclose.com/Our students learn the government contracting skills to :1. Start their own consulting business that can earn up to $400k as a "solopreneur" advising businesses that sell to the government.2. Land high paying sales executive jobs with companies in the public sector.3. Increase government contracting revenue for companies selling to the US government.––––––––––––––––––––––––––––––––––––––RESOURCES MENTIONED––––––––––––––––––––––––––––––––––––––GovClose Program Overview (free 20-minute training): https://www.govclose.comhttps://www.nih.govhttps://www.sbir.govContact Nipun: https://www.choprascience.comNipun's Linkedin: https://www.linkedin.com/in/nipun-chopra-phd-98511b9a/––––––––––––––––––––––––––––––––––––––ABOUT RICK HOWARD––––––––––––––––––––––––––––––––––––––Rick Howard is a retired USAF Lieutenant Colonel and former DoD acquisitions officer who managed over $82 billion in federal contracts. He is the founder of GovClose and the DoD Contract Academy, with 400+ graduates working as government contract consultants, federal account executives, and business owners winning federal contracts.Rick Howard expresses his opinions as a former government contracting officer and presents public data on government contracts that he analyzes. GovClose makes no guarantees whatsoever about federal spending data or government contracts.Government contracting data changes constantly, and we make no claims of perfection when presenting data. All data can be looked at from different angles, and it is up to the viewer to do their own research, their own data analysis, and decide if government contracting is for them.Disclaimer: This video reflects Rick Howard's personal opinions and independent analysis of publicly available government data. It does not represent an official position, endorsement, or statement of the U.S. Air Force or the Department of Defense.

In this episode I talked with Dr. Mary Talley Bowden and Emily Kopp (Senior Investigative Reporter for the Daily Caller). We discussed the recent measles hysteria in Pennsylvania - how Josh Shapiro lied and deceived people about the details to the case and how Trump and RFK responded. We also discussed the newly found CIA ties to the NIH and Anthony Fouci. SIGN UP FOR THE THURSDAY CLUB: https://www.theparadoxpress.com/found... Read Mary Talley Bowden's Article: https://www.theparadoxpress.com/measl... Read Emily Kopp's Articles: https://dailycaller.com/2026/08/28/ex... https:// dailycaller.com/2026/08/28/ex... https://dailycaller.com/2026/09/02/sc... Go subscribe to The Paradox Press now!Follow me on X: https://x.com/andyschmitt99

On this week's episode of The Ultimate Assist, Brianne Dressen returns to sit down with John Stockton and Ken Ruettgers for an explosive update on COVID vaccine injuries, React19, Anthony Fauci, and the information now emerging about what federal health officials were discussing behind closed doors.Brianne's story will already be familiar to longtime listeners. After volunteering for a COVID vaccine clinical trial, she says she experienced a severe reaction following her first dose and was later studied at the NIH and diagnosed with post-vaccine neuropathy. Her experience ultimately led her to help establish React19, a nonprofit advocating for people who report serious and lasting injuries following COVID vaccination. But this time, Brianne isn't simply returning to tell her story.She's bringing updates.Brianne discusses recently surfaced records involving Anthony Fauci and other senior health officials and argues that they provide new insight into what government agencies knew about reported adverse reactions during the early vaccine rollout. She describes the conversations she says were happening among figures including Fauci, Francis Collins, Janet Woodcock and Peter Marks—and asks why the public wasn't given more information about the injuries her organization was reporting. John, Ken and Brianne also dive into the ongoing investigations led by Senators Ron Johnson and Rand Paul, the legal protections surrounding pandemic countermeasures, vaccine-injury compensation, and why Brianne says many injured Americans are still struggling financially and medically years later. The conversation explores Brianne's frustration that even under new leadership, she believes changing the culture inside America's health agencies is proving far more difficult than many expected. As she puts it, the problem goes far beyond any single individual. Brianne also gives a deeply personal update on her own health. After once falling below 100 pounds and struggling with debilitating symptoms, she says her condition today is dramatically improved. She shares what she's learned about pacing, sleep, nutrition, stress, complementary therapies and—perhaps most importantly—having patience and compassion for yourself during chronic illness. What did Fauci and other officials know? When did they know it? Why do vaccine-injured Americans still say they're fighting for recognition? And after five years, are we finally beginning to get answers?

The Morning XTRA with Tug and Los delivers conservative talk on the biggest political, cultural, and news stories of the day. Smart analysis, unapologetic opinions, and real conversations every weekday morning. Every weekday from 6a to 10a! The 8 o'clock hour is brought to you by Central Heating & Air, your Atlanta Carrier Experts. 770-GET-HEAT, Centralheat.com First thing to know: You gotta feel for the GoBear By the Numbers: What happens if the polls underestimate republicans as they always do This is why we watch MSNOW so you don’t have to Watch The Morning XTRA every weekday from 6 a.m. to 10 a.m. on the XTRA 106.3 YouTube or listen on the XTRA 106.3 App

The Morning XTRA with Tug and Los delivers conservative talk on the biggest political, cultural, and news stories of the day. Smart analysis, unapologetic opinions, and real conversations every weekday morning. Every weekday from 6a to 10a! On Today's show, Tug and Los talk about Tug finally watching some good TV and break down how a country can have more than 2,500 people killed without an earthquake. The guys react to Van Jones calling out an extreme position, discuss women using the Lindsay Clancy case as their own O.J. case, and welcome back Tug’s spirit animal. They also look at the latest GoBear saga, crunch the numbers on what could happen if polls once again underestimate Republicans, and explain why they watch MSNOW so you don’t have to. Plus, legal analyst and trial attorney Phil Holloway joins the show to discuss the Lindsay Clancy case. Watch The Morning XTRA every weekday from 6 a.m. to 10 a.m. on the XTRA 106.3 YouTube or listen on the XTRA 106.3 App

Today hear from Julia Oppman, a two time acute myeloid leukemia survivor (AML)and patient advocate from Northeast Ohio. Julia shares how her cancer journey began in 2018 when she was 36 years-old and raising two young children. She initially blamed her extreme exhaustion on motherhood and work. After months of illness and repeated infections, she was diagnosed with AML. The diagnosis came unexpectedly by phone and was followed almost immediately by a 30 day hospital stay for induction chemotherapy. Julia later underwent minimal residual disease (MRD) testing. Eventually, the numbers increased and she relapsed in 2020. She was told that a bone marrow transplant was now necessary to save her life. The transplant took place during the COVID pandemic, creating additional challenges for Julia and her family. Hospital visitor restrictions led them to relocate so she could receive treatment at a hospital that allowed support people. Her husband, mother, and children became an essential part of her care during the transplant and the critical first 100 days afterward. Following transplant, Julia developed chronic Graft Versus Host Disease. She describes it as one of the most challenging parts of her experience because it can affect multiple areas of the body at different times. Her symptoms have required visits with many specialists, and she has struggled to find treatments that work for her. Insurance denials have created another barrier, especially when doctors want to consider medications that are not specifically labeled for Graft Versus Host Disease. Julia has become a strong advocate for herself and others. She sought evaluation at the National Institutes of Health (NIH) and plans to pursue additional expertise at Memorial Sloan Kettering Cancer Center in New York. She encourages patients to look for support groups, connect with others who have similar experiences, and continue searching for medical resources when existing options are not enough. One of Julia's biggest sources of purpose is her 'Share the Love' initiative. What began as Valentine's Day gifts for patients on her hospital floor has grown into an annual effort serving several hospitals, including a children's hospital. Her children now help create handmade Valentines for the packages. Julia also shares the unexpected birth of her youngest child after being told she would not be able to have more children. Through cancer, transplant, chronic GVHD, advocacy, motherhood, and giving back, she continues looking for what she calls the silver lining. Her message is clear. Life after transplant is not always simple or easy. Support often means showing up, listening, helping with every day tasks, and allowing patients to be honest about what they are experiencing. If you want to help Julia's Share The Love initiative, you can reach her at: jewelsjean@hotmail.com Thank you to our Season 21 Sponsors: Incyte: https://incyte.com/ Sanofi: https://www.sanofi.com/ Additional Resources: National Institutes of Health (NIH): https://www.nih.gov/ GVHD Alliance: https://www.gvhdalliance.org/ NeedyMeds: https://www.needymeds.org (00:00) Introduction (01:03) How Julia's cancer journey began (06:04) Relapsing during the COVID pandemic (07:18) Facing a bone marrow transplant in 2020 (08:09) Relocating the family and finding caregiver support (11:03) Creating the Share the Love Valentine's initiative (13:31) Living with chronic graft versus host disease (15:51) Resources for medication assistance (16:08) Seeking answers at NIH and Memorial Sloan Kettering (19:58) Support groups and learning from other patients (21:14) An unexpected pregnancy after transplant (23:31) Insurance barriers and financial toxicity (24:37) Putting the broken pieces of life back together (27:05) How friends can truly support patients National Bone Marrow Transplant Link - (800) LINK-BMT, or (800) 546-5268.nbmtLINK Website: https://www.nbmtlink.org/Check out our valued nbmtLINK resource books, some for sale, some free as downloadable, https://www.nbmtlink.org/shop/nbmtLINK Facebook Page: https://www.facebook.com/nbmtLINKFollow the nbmtLINK on Instagram! https://www.instagram.com/nbmtlink/The nbmtLINK YouTube Page can be found by clicking here.This content is provided for informational purposes only and is not intended to substitute for professional medical advice, diagnosis, or treatment. It is crucial to consult directly with a qualified healthcare professional regarding any medical conditions, treatment options, or other health concerns.The views and opinions expressed by the speakers are their own and do not necessarily reflect the official policy or position of the nbmtLINK. Unless otherwise stated in an official policy, the nbmtLINK does not endorse any specific treatments, products, or services mentioned by the speakers. Reliance on any information provided is solely at your own risk.The Marrow Masters Podcast is produced by JAG Podcast Productions: https://jagpodcastproductions.com/ Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Nutrition is finally getting a seat at the medical education table. Dr. Jaclyn Albin, the new President of the American College of Culinary Medicine (ACCM), joins Dr. Sabrina Falquier to discuss strategies for weaving nutrition into medical education, and explains why a hands-on teaching kitchen can stick with learners in a way slides never will.  Dr. Albin also makes a compelling case for the broader team required to move this work forward, including chefs, dietitians, researchers, behavioral health professionals, public health experts, occupational therapists and farmers.  If you work in healthcare, teach, study or just want evidence-based answers about food and health, this conversation shows why the future of medicine is also being built in kitchens, not just lecture halls.In this episode we cover:·      Who is Dr. Jaclyn Albin [1:10]·      The role of nutrition in healthcare [1:50]·      Does nutrition belong in medical school curriculum? [3:30]·      No, we're not trying to turn doctors into dietitians. [5:30]·      Bridging silos to fix chronic disease and a broken food system [6:20]·      Why hasn't nutrition been historically part of medical education? [8:25]·      The difference between nutrition and culinary medicine [10:10]·      Different approaches to teaching nutrition in medical school [12:40]·      How Dr. Albin got into culinary medicine [16:45]·      Where we are today with nutrition education in medicine [20:00]·      Teaching kitchens [24:00]·      Two examples of a culinary medicine medical school elective [26:40]·      Ideal culinary medicine team [29:00]·      Where can MD's get evidence-based nutrition education? [32:30]·      What does success in culinary medicine look like? [35:50]ResourcesHealthy Eating Plate: Your Guide to Balanced Meals - https://youtu.be/riywZ8QtFdAWhat Do Doctors Actually Learn About Nutrition - https://alternativefoodnetwork.com/podcasts/episode-34-what-do-doctors-actually-learn-about-nutrition/Subscribe and Review: If you're passionate about the future of lifestyle medicine and healthcare innovation, subscribe and leave us a review. Your feedback helps us bring more evidence-based Culinary Medicine content to your feed.Credits:Host – Dr. Sabrina Falquier, MD, CCMS, DipABLMSound and Editing – Will CrannExecutive Producer – Esther Garfin©2026 Alternative Food Network Inc.Dr. Sabrina Falquier is a board-certified physician and a leader in Culinary Medicine. She specializes in bridging the gap between scientific evidence and the actual food on your plate, empowering listeners to use the kitchen as a place of wellness and healing.Show Topics Include: Nutrition, Food as Medicine, Health and Wellness Podcasting, Microbiome, Metabolism, Weight loss, Gut health, Healthy recipes, Health, Inflammation, Longevity, Blood sugar, Protein, Magnesium, Sleep quality, Immunity, Hormone balance, Sunday meal prep, Medically tailored meals (MTM), Produce Prescription (PRx), Prevention, Teaching kitchen, Health equity, Evidence-based nutrition, food podcast insights

The Nurses Report on America Out Loud with Gail Macrae, BSN, RN – That system is four agencies working in concert. NIH funds the papers that supply the narrative. CDC turns the narrative into recommendations. CMS attaches the money. FDA supplies the EUA that makes the whole chain legally possible. It is a network. Subpoena power exists to pull the records those agencies already...

G.K. opens this week's Mining the Media with two New Nuggets available exclusively at MiningTheMedia.com: an NIH-funded study finding that puberty blockers failed to improve youth mental health, and a striking comparison of the enormous land requirements of solar and wind energy versus nuclear power. Then G.K. brings Dave something he hadn't seen: "A Mike Johnson power move can neuter the DSA — and make Democrats pick a side." What political maneuver is the Speaker considering, and why could it force members of Congress to publicly choose between the Democratic Socialists of America and the broader Democratic Party? Then Dave takes the microphone for a deeply personal Crusty's Corner: "Who Had Access? — The Troubling Questions Surrounding Presidential Security." An armed man allegedly surveilled federal agents preparing for a presidential visit, falsely claimed to be part of a State Department security detail, and was later found with extensive writings reportedly containing schedules involving First Lady Melania Trump and Secret Service personnel. Drawing carefully upon decades of experience in military aviation, airspace management, homeland defense, and classified environments—without revealing what should remain protected—Dave asks the question that refuses to go away: How did he know? This isn't about exposing the secrets that protect America's First Family. It's about demanding that the people entrusted with those secrets determine whether they remained secret. Please be sure to visit our website at www.miningthemedia.com and share it with your friends, relatives, associates, and neighbors.

Clint and Wendy explore the physical, mental, and emotional effects of meditation, citing sources like the NIH's National Center for Complementary and Integrative Health. Different types of meditation, such as focused attention, mindfulness, and loving-kindness, have distinct benefits. The potential negative effects, including anxiety and depression, and the importance of proper guidance. Wendy shares a personal story about using tapping to heal childhood trauma.

MedPod Today: the podcast series where MedPage Today reporters share deeper insight into the week's biggest healthcare stories. This week, MedPage Today reporters discuss why a physician group is suing the government over the most recent dietary guidelines, an expensive new NIH policy, and a pediatrician running to succeed Lindsay Graham. Episode produced and hosted by Rachael Robertson. Sound engineering by

A battle erupts between RFK Jr. and Pennsylvania Governor Josh Shapiro over two “measles-associated” deaths, vaccine misinformation, and the use of abortion-derived fetal cell lines in MMR production.Jefferey Jaxen investigates Merck's claim that fulfilling President Trump's order to split the MMR vaccine could take up to a decade. Plus, Fauci launches a legal defense fund as scrutiny of the COVID lab-leak cover-up intensifies.As closing arguments conclude in the Lindsay Clancy trial, Del sits down with board-certified clinical psychologist Dr. Roger McFillin to examine Clancy's psychiatric-drug history and ask whether the pharmaceutical industry belongs on trial, too.Then, Del checks in with MAPS President Dr. James Neuenschwander about a MAPS physician's appointment to the NIH and the upcoming MAPS conference.Guests: Aaron Siri, Esq., James Neuenschwander, M.D., Roger K. McFillin, Psy.D., ABPPAirdate: August 27, 2026Become a supporter of this podcast: https://www.spreaker.com/podcast/the-highwire-with-del-bigtree--3620606/support.

At The International Anesthesia Research Society (IARS) and Society of Critical Care Anesthesiologists (SOCCA) meeting in Montreal, TopMedTalk hosts Mike Grocott and former editor-in-chief Desiree Chappell speak with FAER board members Dr. Rebecca A. Aslakson, Chair and Professor with Tenure, Department of Anesthesiology, University of Vermont Health Network and Dr. Michael Gropper, Professor and Chair of the UCSF Department of Anesthesia and Perioperative Care, about the Foundation for Anesthesia Education and Research (FAER). We describe how FAER's early-career support—especially the Mentored Research Training Grant—helped launch our guest's own research trajectories and facilitates transition to larger funding, with about 60% of MRTG recipients later obtaining NIH funding. They outline FAER's origins (founded in 1986 in partnership with the ASA), funding mechanisms spanning medical students to early faculty, partnerships with multiple specialty organizations, and career development resources including networking, mock study sections, and a National Academy of Medicine collaboration, emphasizing mentorship and community as central to long-term research success. -- Find out more about EBPOM Dingle now: www.ebpom.org

Announcements: Public comment period on the Thomas Paine Memorial @3:57 News: Kennedy Center threat @5:00 CIA director 'on secret trip to Moscow' as US military plane lands at airport @5:39 Supreme Court Allows Trump to Pursue Mail Voting Limits, for Now @11:05 Politics: Unhinged White House response shows senator's ‘Natalie' barb struck a nerve @14:23 FBI Agents Search Eric Swalwell's Home as Part of Federal Sexual Assault Inquiry @25:10 Ken Paxton and the Curious Case of the Missing $1,000 Pen @27:28 Religious Nonsense: Supreme Court asked to block Ten Commandment displays @35:29 Colorado district to reject controversial reading curriculum @37:34 Survivors Just Built the First National Database of Accused Protestant Abusers @38:38 Health/Medicine/Science: Neurologist with MAHA ties to lead NIH's child health institute @40:59 How Louisiana's New Surgeon General Wants To Transform Public Health @42:57 Two Unvaccinated People Died from Measles in Pennsylvania, Officials Say @44:02 Kentucky health officials have announced a new measles outbreak @47:28 Kindergarten vaccination rates @47:38 CDC's Zombie Programs @49:07 Pseudoscience: Structured Water: Distilling the Science from the Non-Potable Claims @50:27 Final Stories: Colorado GOP Gov Nominee Claims to Have Battled ‘Demons' @52:32

Dr. Fauci's pleading of the Fifth 111 times in a recent Senate hearing outraged many Americans. Far before the Senate, in Missouri vs. Biden (2026), in which Dr. Kheriaty was a plaintiff, Dr. Fauci pleaded the Fifth 168 times; the Justice Department recently ruled in his favor. It is understandable, then, that many have had cause for outrage for many years. Some paid for COVID lockdowns and irrational mandates with their livelihoods, including Dr. Kheriaty, who was fired from UC-Irvine's School of Medicine after he challenged their COVID vaccine mandate in Federal Court. Others, unfortunately, paid for these pandemic-era policies with their lives. What these hearings revealed is something that can't be unseen: the U.S. healthcare system rests on an enormous amount of unchecked power. A solution is needed. Drs. Kheriaty and Orlandi discuss this and more on this episode of What We Can't Not Talk About.Timeline Summary [0:00] – Introduction and welcome; Dr. Orlandi welcomes back Dr. Aaron Kheriaty of the Ethics and Public Policy Center. [1:48] – Seeing American medicine with an outsider's eye, and why this conversation could not wait. [3:35] – Challenging UC Irvine's vaccine mandate in federal court, and being fired for it. [5:22] – Censored for saying true things: what could and could not be said about the COVID shots. [7:07] – Missouri v. Biden, the government's own admissions, and Fauci under oath for the first time. [8:53] – “I don't recall”: amnesia for the most consequential decisions of the pandemic. [10:42] – Why no credible scientist says “The Science”: conjecture, refutation, and the method itself. [12:28] – What Fauci's government records actually show, and why they are fair game for the public. [14:14] – Scott Atlas's memoirs, and the pattern that was clear long before the Senate hearing. [16:03] – The New Abnormal: a man used by the media, the biosecurity apparatus, and financial interests. [17:49] – Refusing responsibility, and the more controversial point Dr. Orlandi wants to make. [19:37] – Why this must not happen again: honest scientists, royalties, and the temptation of power. [21:22] – The NIH's grip on American medical research, and what the purse strings buy. [23:12] – Doctors who harboured private doubts and would not say in public what they wrote in email. [24:59] – “Prove me wrong” in an age when nobody can be proved wrong, and dogma dressed as science. [26:48] – Flattery and flatterers: why people in authority must sift what their critics say. [28:37] – Weak leaders and strong leaders; Lincoln, and surrounding yourself with better people. [30:23] – The despair crisis that predated COVID, and what isolation actually did to patients. [32:11] – The Other Pandemic: the lockdown mental health crisis, and the CDC's own evidence. [33:58] – The disingenuous framing that critics of lockdowns put money ahead of public health. [35:43] – All-cause mortality at record highs, and the data that was suppressed at the time. [37:29] – Propaganda's cruellest trick: the guilt that stops you looking again. [39:15] – A suggestion for anyone willing to revisit what they believed, and a turn towards medicine. [41:02] – Gain-of-function research, lab leaks, and why staying calm is the first thing to do. [42:49] – Mask theatre on the way to the table: do not outsource logic or common sense. [44:34] – Targeted advice, monetised data, and health guidance that does not look like selling. [46:20] – Trust your instincts and the people who care about you; simple advice patients can follow. [48:06] – Why medicine chases weight loss, and the money in treatment rather than prevention. [49:52] – A competing theory of cancer, available since the 1930s and largely ignored. [51:37] – Ozempic, Botox, and the message that there is a magic pill for every problem. [53:23] – Where these drugs do make sense, and why cosmetic use fails the risk-benefit test. [55:11] – Cheap toxic food, expensive healthy food, and why obesity is not simple laziness. [56:58] – Contraceptive estrogens in the water supply, fertility, and the costs pushed onto families. [58:45] – Courage, staying in the fight, and having someone in Washington you can call. [1:00:32] – “Social distancing” rather than physical distancing, and the bonds it broke. [1:02:18] – Turn the screen off: getting away from rage bait and doom scrolling.Links & Resources Dr. Kheriaty's New Book, Making the Cut: https://www.skyhorsepublishing.com/9781510784215/making-the-cut/ Dr. Kheriaty's Recent Article on First Things: https://firstthings.com/icarus-descending/ Dr. Orlandi's Review of Making the Cut on Substack: https://substack.com/home/post/p-172888363 Dr. Kheriaty's Previous Appearance on WWCNTA: https://youtu.be/AfANnnwNmzA?si=_drMqtSP1HTKslz_ Missouri v. Biden/Murthy v. Missouri Summary: https://firstamendment.mtsu.edu/article/missouri-v-biden-consent-decree-2026/ Austin Institute: https://www.austin-institute.org/

Keeping your clients coming back is crucial to the success of your insurance business. But how often should we reach out to clients? How do we reach out without being annoying? Where do we start? If you've ever asked these questions, don't miss the ASG Podcast interview with Bjorn Piltingsrud and Andrew Saksa from Essential Engine!   Resources: Essential Engine Official Website Listen to Marketing MindFuel Reach out to Andrew Saksa at Essential Engine Schedule a Meeting with Mel Binford from Essential Engine   References: Lindenfors, Patrik, et al. “‘Dunbar's Number' Deconstructed.” Pmc.Ncbi.Nih.Gov, U.S. National Library of Medicine, May 2021, pmc.ncbi.nlm.nih.gov/articles/PMC8103230/. “Dunbar's number: Why we can only maintain 150 relationships.” Bbc.com, BBC, https://www.bbc.com/future/article/20191001-dunbars-number-why-we-can-only-maintain-150-relationships, Accessed 2 June 2026.   Follow Us on Social! Ritter on Facebook, https://www.facebook.com/RitterIM Instagram, https://www.instagram.com/ritter.insurance.marketing/ LinkedIn, https://www.linkedin.com/company/ritter-insurance-marketing TikTok, https://www.tiktok.com/@ritterim X, https://x.com/RitterIM and YouTube, https://www.youtube.com/user/RitterInsurance      Sarah on LinkedIn, https://www.linkedin.com/in/sjrueppel/ Instagram, https://www.instagram.com/thesarahjrueppel/ Threads, https://www.threads.net/@thesarahjrueppel  and Bluesky, https://bsky.app/profile/sarahjrueppel.bsky.social  Not affiliated with or endorsed by Medicare or any government agency.

(0:00) Michael Kratsios joins the show! (01:56) Is this administration anti-science? The Nature poll, DEI grants, and $8B down the drain  (8:16) Climate science cuts: RCP 8.5 gets pulled and the "climate emergency" narrative collapses (13:45) $47B at NIH, Eroom's Law, and golden tickets: has American science stagnated?  (22:24) Big bold bets: Genesis Mission, quantum by 2028, fusion by 2035, boots on the moon in '28  (34:04) The great race with China: $33B to $670B, and 7 out of 10 STEM PhDs aren't American  (44:09) Fauci did more damage to science than anyone in modern history, and NIH's median researcher is 71 Follow the besties:  https://x.com/chamath https://x.com/Jason https://x.com/DavidSacks https://x.com/friedberg   Follow on X: https://x.com/theallinpod   Follow on Instagram: https://www.instagram.com/theallinpod   Follow on TikTok: https://www.tiktok.com/@allin   Follow on LinkedIn:  https://www.linkedin.com/company/allinpod   Intro Music Credit: https://rb.gy/tppkzl https://x.com/yung_spielburg   Intro Video Credit: https://x.com/TheZachEffect #allin #tech #news  

TWiV describes a human cerebral organoid model for Ebola virus persistence, and brown bullhead catfish melanoma, a novel transmissible cancer. Hosts: Vincent Racaniello, Alan Dove, and Rich Condit Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support science education at MicrobeTV Revamp of how NIH scores research grant proposals (Nature) Kansas BSL-4 lab faces more delays (Science) Ebola virus persistence in a human cerebral organoid model (Nat Micro) Hidden cost of immune privilege (Nat Micro) Transmissible melanoma of catfish (Nature) Skin cancer spreads between catfish (Nature) Tasmania devil cancer vaccine (Nature) Letters read on TWiV 1351 Timestamps by Jolene Ramsey. Thanks! Picks of the Week Rich – The Faith of Beasts by James S.A. Corey Alan – Ingrained, by Callum Robinson Vincent – NYC's 5 Broken Skyscrapers — Which One Dies First? Intro music is by Ronald Jenkees Send your virology questions and comments to twiv@microbe.tv Content in this podcast should not be construed as medical advice.

In this fiery segment, the discussion dismantles lingering political narratives regarding law enforcement statistics and the 2020 unrest, contrasting public perceptions with published research findings. The focus then shifts to newly unsealed communications involving key NIH-affiliated researchers, exposing efforts to suppress the COVID-19 lab leak hypothesis and circumvent FOIA requests surrounding Wuhan research funding. --- ### Voting Resources To check your voter registration status or access general election information in South Carolina, refer directly to official state resources: * Locate voter registration details and county election board information via the [South Carolina Election Commission](https://scvotes.gov/). * Manage voter records and access online portal services on [My SC Votes](https://vrems.scvotes.sc.gov/). * Start a new registration or update existing address details through the [SC Online Voter Registration System](https://vrems.scvotes.sc.gov/ovr/start). --- George Floyd Riots, Police Statistics, Anthony Fauci, Wuhan Lab Leak, EchoHealth Alliance, FOIA Conspiracy, Media Narrative, SC Politics

Recorded live from BIO 2026 in San Diego, Gil sits down with Sam Chung, Senior Vice President of Government Relations and External Affairs at California Life Sciences (CLS), to examine a stark and urgent question: Is America's leadership in biomedical innovation still a given? Against the backdrop of NIH funding cuts, a 34% drop in San Diego venture capital, California's post-2030 R&D tax credit rollback, and China's explicit, government-backed commitment to dominating the global life sciences sector, Chung delivers a data-driven, candid, and at times sobering assessment of the headwinds threatening what he calls the "crown jewel" of the California economy. The conversation covers clinical trial timelines, IP migration, talent flight, and what policymakers at both the state and federal level must do to preserve American biomedical leadership before it becomes a historical footnote. To stream our Station live 24/7 visit www.HealthcareNOWRadio.com or ask your Smart Device to “….Play Healthcare NOW Radio”. Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen

Did top health officials use lockdowns and mandates to delay natural immunity? We examine new revelations from Jeffrey Tucker and Brownstone Institute on the true agenda behind COVID restrictions and what it means for public trust.(Enjoyed this quick breakdown? Make sure to follow/subscribe, leave a 5-star review, and join the discussion over on X, Youtube, or Rumble!)Welcome to Actuali, where we explore the crisis of meaning in our world today, and how we may help usher in an awakening from it.In this episode, we break down stunning insights shared by Jeffrey Tucker regarding private acknowledgments from top FDA and NIH officials. We analyze how policies like "flatten the curve," business shutdowns, and outdoor restrictions served to prolong the timeline rather than resolve the crisis naturally, and we look at the devastating 60% loss among American small businesses.We also examine the contradictions of early mitigation strategies—from mask mandates and plexiglass barriers to invasive early intubation protocols. From regional case studies in Africa and the Dakotas to personal accounts of coercion and institutional compliance, we explore the cultural and psychological fallout of federal mandates and why local resilience in communities like Appalachia remains essential.Join us as we explore the ongoing demand for transparency, the ethics of informed consent, and how we make sense of institutional betrayal.Public Health Context & Official Records:Brownstone Institute & Public Policy Records:https://brownstone.orgCenters for Disease Control and Prevention Public Health Recommendations & Timelines:https://www.cdc.gov/coronavirus/2019-ncov/index.htmlWhat do YOU think? Did the push to "flatten the curve" intentionally delay a natural resolution to the pandemic? Drop your thoughts in the comments below

Katie sits down with Dr. Sharon Malone at the Aspen Institute to talk about why women's health has been under-researched and under-funded for centuries -- which also happens to be the subject of Katie's new documentary, HORMONAL!. The numbers are staggering: PMS affects 90% of women but gets a fraction of the funding erectile dysfunction research receives. The NIH didn't require women to be included in clinical trials until 1993. Katie also shares how her own breast cancer diagnosis has shaped her relationship to hormone therapy. It's a candid, infuriating, ultimately hopeful conversation about what it will take to close the gender gap in medicine. Hosted on Acast. See acast.com/privacy for more information.

P.M. Edition for Aug. 18. Government bonds are getting hammered in the U.S. and overseas. WSJ markets reporter Sam Goldfarb discusses how the AI boom is playing a part in driving yields of the 30-year Treasury and other long-term bonds to their highest levels in decades. Plus, Disney steps up a fight with the FCC over a challenge to ABC's broadcast licenses. We hear from media reporter Joe Flint about why Disney sued the government agency, the latest front in the battle between the two that started last year. And there's a secret word game that Bank of America CEO Brian Moynihan plays with Wall Street analysts. Is your vocabulary as good as his? Try our quiz. Alex Ossola hosts. The AI Therapist: A WSJ Podcast Series Sign up for the WSJ's free What's News newsletter. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This time it's Back to Basics -- describing two of the four main components that make up the structure of wine - Acidity & Tannin. It's both simple, and very dorky (I quote the NIH at one point, worth a listen!)   In this show I go back to basics and talk about structure. As I said in the book, I think of wine like a picture frame -- the sides have to be even for it to work. I liken the structure of wine to art and talk a little about the Mona Lisa and how it relates to the four main elements of structure: tannin, acidity, alcohol, sugar (or lack of sugar) plus the flavors of wine in my favorite wine analogy.   Then I discuss acidity and tannin: What they are Their roles in wine Where they come from How they are measured How we perceive them Examples of grapes with high and low acidity/tannin How these sturctural elements interact with other structural elements in wine     Full show notes and all back episodes are on Patreon. Join the community today! www.patreon.com/winefornormalpeople _______________________________________________________________ CHECK OUT MY NEW SPONSOR!!!  This show is brought to you by my NEW exclusive sponsor, Grapes the Wine Company – an actual brick and mortar store located in White Plains, New York that has been recognized by the Wall Street Journal as one of the most influential wine retailers in America. It is a store owned by my friend Daniel Posner, who has been on the show! When I was looking for a new sponsor, I wanted a small retailer who had the flexibility, contacts,  and know-how to get us the wines that we really want. I'm so thrilled that Daniel is now a part of our Wine For Normal People community and I hope you will support him by going to https://www.grapesthewineco.com/   

Cannabis is often discussed as either a miracle remedy or a dangerous drug, but the reality is far more nuanced. In this episode, Dr. Jen speaks with naturopathic doctor and cannabinoid researcher Dr. Michelle Sexton about the endocannabinoid system, medical cannabis, chronic pain, sleep, inflammation, menopause, and opioid reduction. They explore why dose, age, product quality, delivery method, and THC potency all matter, how cannabis differs from CBD, and why modern high-potency products are not the same as the cannabis used decades ago. Dr. Sexton also shares practical guidance on starting low, avoiding unnecessary exposure during brain development and pregnancy, and using cannabis as a carefully considered medical tool rather than a one-size-fits-all solution.Dr. Michelle Sexton, ND, is a licensed naturopathic doctor, researcher, author, and internationally recognized expert on cannabinoid pharmacology and the endocannabinoid system. She completed her naturopathic medical training at Bastyr University and an NIH-funded postdoctoral fellowship at the University of Washington, where she studied cannabis, immune function, neuroinflammation, and neurodegeneration. Dr. Sexton has also served as an Assistant Adjunct Professor in the Department of Anesthesiology at UC San Diego and has worked with patients through the university's Center for Integrative Medicine. Her work focuses on translating cannabinoid science into responsible, practical guidance for pain, sleep, inflammation, women's health, and opioid reduction. Website: https://www.msextonnd.com LinkedIn: https://www.linkedin.com/in/michelle-sexton-a40408b  Facebook: https://www.facebook.com/msextonnd  PODCAST: Thank you for listening please subscribe and share! Shop supplements: https://healthybydrjen.shop/CHECK OUT a list of my Favorite products here: https://www.healthybydrjen.com/drjenfavoritesFOLLOW ME:Instagram: https://www.instagram.com/integrativedrmom/Facebook:  https://www.facebook.com/integrativedrmomYouTube: https://www.youtube.com/@integrativedrmomFTC: Some links included in this description might be affiliate links. If you purchase a product through one of them, I will receive a commission (at no additional cost to you).  I truly appreciate your support of my channel. Thank you for watching! Video is not sponsored.DISCLAIMER: This podcast does not contain any medical or health related diagnosis or treatment advice. Content provided on this podcast is for informational purposes only.  For any medical or health related advice, please consult with a physician or other healthcare professionals. Further, information about specific products or treatments within this podcast are not to diagnose, treat, cure or prevent disease.

Na série de conversas descontraídas com cientistas, chegou a vez da Professora, Pesquisadora, graduada em Economia, com Mestrado e Doutorado em Sociologia, atual Chefe do Grupo de Demografia da Universidade da Pensilvânia, Leticia Marteleto. Só vem! >> OUÇA (88min 57s) * Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza. Edição: Reginaldo Cursino (@reginaldocursino) Ilustração e Capa: Felipe Cruz (@felipecruzart) http://naruhodo.b9.com.br * Leticia Junqueira Marteleto possui graduação em Economia pela Universidade Federal de Minas Gerais (1995), mestrado em Sociologia com ênfase em Demografia pela Bowling Green State University (1997), mestrado em Metodologia de Survey pela University of Michigan (2000) e doutorado em Sociologia com ênfase em Demografia pela University of Michigan (2001). Foi pesquisadora associada e professora colaboradora dos Departamentos de Demografia/Cedeplar e Sociologia da Universidade Federal de Minas Gerais (2001-2004). Tem pós-doutorado pela University of Michigan (2004-2008), onde atuou também como pesquisadora do Institute for Social Research (ISR) e do Population Studies Center (PSC) e como professora do Departamento de Estudos Educacionais da Escola de Educação (2008-2009). Foi consultora residente da Divisão de População das Nações Unidas (2007-2008) em Fecundidade, tendo preparado relatórios sobre Adolescência e os Objetivos do Milênio. Foi professora associada (com tenure) do Departamento de Sociologia da University of Texas em Austin e pesquisadora associada do Population Research Center (PRC) e do Lozano Long Institute for Latin American Studies (LLILAS). Atualmente, é Professora Titular de Sociologia da Universidade da Pensilvânia, onde também é Chefe do Graduate Group in Demography (GGD). Atua nas áreas de demografia social, demografia da família, fecundidade, estudos educacionais, métodos quantitativos, desigualdades sociais e raciais com enfoque principalmente no Brasil, América Latina e África do Sul. É InvestigadoraPrincipal do projeto DZC, financiado pela NIH, o primeiro survey longitudinal sobre vida reprodutiva e fecundidade no Brasil. Site: https://web.sas.upenn.edu/leticia-marteleto/ * APOIE O NARUHODO! O Altay e eu temos duas mensagens pra você. A primeira é: muito, muito obrigado pela sua audiência. Sem ela, o Naruhodo sequer teria sentido de existir. Você nos ajuda demais não só quando ouve, mas também quando espalha episódios para familiares, amigos - e, por que não?, inimigos. A segunda mensagem é: existe uma outra forma de apoiar o Naruhodo, a ciência e o pensamento científico - apoiando financeiramente o nosso projeto de podcast semanal independente, que só descansa no recesso do fim de ano. Manter o Naruhodo tem custos e despesas: servidores, domínio, pesquisa, produção, edição, atendimento, tempo... Enfim, muitas coisas para cobrir - e, algumas delas, em dólar. A gente sabe que nem todo mundo pode apoiar financeiramente. E tá tudo bem. Tente mandar um episódio para alguém que você conhece e acha que vai gostar. A gente sabe que alguns podem, mas não mensalmente. E tá tudo bem também. Você pode apoiar quando puder e cancelar quando quiser.  O apoio mínimo é de 15 reais e pode ser feito pela plataforma ORELO ou pela plataforma APOIA-SE. Para quem está fora do Brasil, temos até a plataforma PATREON. É isso, gente. Estamos enfrentando um momento importante e você pode ajudar a combater o negacionismo e manter a chama da ciência acesa. Então, fica aqui o nosso convite: apóie o Naruhodo como puder. bit.ly/naruhodo-no-orelo

On this week's episode of the RealClearInvestigations Podcast, RCI Editor J. Peder Zane and RCI Senior Reporter James Varney speak with the Substacker who writes under the pseudonym “Yuri Bezmenov” (he'll tell us why) about his reporting on the network of awards, fellowship, teaching gigs and other lucrative and prestigious incentives that reward people who espouse progressive ideas. On the news round-up, Zane and Varney discuss a National Review article that details Iran's efforts to take the war to other countries, a ProPublica article about how General Dynamics' failed effort to make artillery shells with robots cost American taxpayers hundreds of millions of dollars and an article in the Atlantic in which an African-American professor details how his experience with dangerous excesses of wokism pushed him to leave academia. Articles Discussed in This Podcast:| Yuri Bezmenov Substack: Fauci's Georgetown Gig and Other Progressive Rewards National Review: Iran Is Rewiring Its Proxy Network ProPublica: Taxes Funded $533M Artillery Plant That Made Nothing Atlantic: Why This Black Professor Quit the Tenure Track Sign up for the RealClearInvestigations Newsletter. Watch each episode on the RealClearPolitics YouTube ChannelContact us with your thoughts and feedback: jpederzane@realclearinvestigations.com

What did Dr. Anthony Fauci know privately about COVID vaccines—and what was the American public being told at the same time? On this episode of The Truth with Lisa Boothe, Senator Ron Johnson joins Lisa for an explosive conversation about his ongoing investigation into the government's COVID-19 response and newly obtained communications from Fauci’s government-issued devices. Johnson discusses a private Fauci message that he says raised concerns about vaccination and pregnancy, why he believes the issue goes far beyond the debate over miscarriage statistics, and his argument that Americans were denied information necessary to make fully informed medical decisions. The Wisconsin senator also reveals what investigators are finding as they work through tens of thousands of Fauci text messages, hundreds of voice messages and other government records. Johnson explains why identifying the people behind hundreds of phone numbers has become a critical part of the investigation—and why he says his team is being careful not to release private information unrelated to public policy. Lisa and Sen. Johnson also discuss Fauci’s handling of the COVID pandemic, gain-of-function research, vaccine safety surveillance, the relationship between government health agencies and pharmaceutical companies, and Johnson’s allegations that career bureaucrats are resisting efforts to uncover additional records. Johnson says investigators are now seeking devices and communications associated with other former government health officials as his probe expands—and declares that despite years of pursuing answers about the pandemic, the investigation has “only just begun.” Plus, Johnson explains why he believes America still needs a full COVID reckoning before the next public health crisis.See omnystudio.com/listener for privacy information.

What happens when someone who volunteered for a COVID-19 vaccine clinical trial says the shot changed her life within hours? On this episode of The Tudor Dixon Podcast, Tudor sits down with Brianne Dressen, co-founder of React19 and a participant in the AstraZeneca COVID-19 vaccine clinical trial, to discuss her experience with what she describes as a severe and lasting vaccine injury. Dressen recounts developing neurological symptoms shortly after receiving the shot, including burning and tingling, numbness, difficulty walking, sensitivity to light and sound, vision problems, and cognitive issues. She says some symptoms remain with her nearly six years later. She also describes receiving treatment at the National Institutes of Health, saying the intervention produced a significant improvement but that she has continued to require treatment. Tudor and Dressen discuss informed consent during vaccine trials, the treatment of people reporting adverse events, Anthony Fauci and the NIH, pharmaceutical-company accountability, and Dressen's allegations that officials knew more about certain adverse effects than was publicly acknowledged. Dressen also explains why she believes further federal investigation is necessary. It’s a wide-ranging conversation about one woman's experience, unanswered questions from the COVID era, and the continuing debate over transparency, medical treatment, and accountability. Subscribe to The Tudor Dixon Podcast on iHeartRadio, Apple Podcasts, YouTube, and wherever you get your podcasts.See omnystudio.com/listener for privacy information.

In this episode of John Solomon Reports, host John Solomon dives into the latest revelations surrounding Dr. Anthony Fauci's communication during the COVID-19 pandemic. Solomon highlights the stark contrast between Fauci's public statements and his private concerns, particularly regarding the safety of the COVID vaccine for pregnant women. Drawing from newly uncovered text messages, Solomon discusses how Fauci seemed apprehensive about the risks of miscarriage associated with the vaccine, raising critical questions about transparency in public health messaging.Joining Solomon is Dr. Jay Bhattachara, the current director of the National Institutes of Health, who sheds light on the cultural shifts within the NIH following Fauci's tenure. Bhattachara emphasizes the importance of humility and scientific debate in the agency's future direction, moving away from the politics that have previously overshadowed scientific discourse.The episode also features Congressman Rudy Yakym from Indiana, who shares his candid thoughts on Fauci and the current Senate dynamics. Yakim discusses the ongoing manufacturing renaissance in America, sparked by recent policy changes, and expresses his frustrations with the legislative process in the Senate.Finally, listeners can look forward to a health news update brought to you by our great partners and friends at NativePath. Dr. Chad Walding provides listeners with the latest developments in health and wellness.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

August 11, 2026, 5pm; The Washington Post reveals how when faced with an assassination threat from Iran, Trump secretly flew back from the NATO summit last month in Turkey via an alternate aircraft -- despite saying he was flying home in Air Force One. For more from Nicolle, follow and download her podcast, “The Best People with Nicolle Wallace,” wherever you get your podcasts.To listen to this show and other MS podcasts without ads, sign up for MS NOW Premium on Apple Podcasts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

This special episode features the Munk Debate on the Gene Editing, held before a live audience of 800 students and faculty at Deerfield Academy in April 2026.Arguing in favour of the motion was the biophysicist, best-selling author, biotechnology entrepreneur, and the former director of the Program on Medicine, Technology and Society at UCLA School of Medicine, Gregory Stock. His debate partner was the internationally acclaimed strategic philosopher and pioneering transhumanist Max More. Arguing against the motion was the prominent American bioethicist Ezekiel Emanuel, Special Advisor to the Director General of the WHO and a former founding chair of the Department of Bioethics at the NIH. His debate partner wass the award-winning educator, author, and Professor of Reproductive Science at University College London, Joyce Harper.Become a Munk Donor ($50 annually) to get 72-hour advanced access to the full length editions of Friday Focus and Munk Dialogues. Go to www.munkdebates.com to sign up. Hosted on Acast. See acast.com/privacy for more information.

In this episode of John Solomon Reports, host John Solomon uncovers two significant stories that shine a light on accountability and transparency in government. The first revelation comes from Solomon's role as chairman of the White House Government Transparency Task Force, where he discusses the declassification of documents showing that former Attorney General Jeff Sessions was placed under criminal investigation by his own team shortly after taking office. Solomon highlights the flimsy basis for this investigation, which stemmed from a letter and concerns raised by Democrats, revealing a troubling pattern of political maneuvering within the FBI during the Trump administration.The second major scoop involves the release of Anthony Fauci's text messages from his time at the NIH, which reveal his private concerns about the COVID vaccine's potential risks for pregnant women. Solomon emphasizes the stark contrast between Fauci's public statements and his private beliefs, raising critical questions about the transparency of public health messaging during the pandemic. The episode also features insights from Louisiana Attorney General Liz Murrill, who is investigating Fauci's actions, and Congressman Marlin Stutzman, who discusses the implications of license plate cameras and a bold proposal to reform foreign aid to Israel.Finally, Solomon celebrates the 250th birthday of America with the owners of the Monocle, a beloved Washington restaurant known for bridging partisan divides. See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Jay Bhattacharya returns to GoodFellows—now as NIH director and acting CDC director—for a candid conversation on what COVID got wrong, why science needs a replication revolution, and how to restore public trust. Jay takes on the legacy of lockdowns, school closures, Fauci, gain-of-function research, China, AI-enabled biosecurity risks, vaccine questions, and the fight to make scientific dissent possible again. Then: Iran, the Strait of Hormuz, AI guardrails, democratic socialism, and what Homer can still teach us about war. Subscribe to GoodFellows for clarity on today's biggest social, economic, and geostrategic shifts — only on GoodFellows.

A 10-year presidential pardon is quite a thing. But will it be enough to protect Tony Fauci from ALL of his alleged nefarious misdeeds? No, says Dr. David Martin, the researcher who comes with the patent receipts to show how long Fauci and Ralph Baric were tinkering with gain of function research on corona viruses. CNN news hack Dana Bash gets schooled by RFK Jr. as we may start to hear more from Margaret Moore, the FOIA liaison to the NIH who pleaded the fifth two years ago. Why was she teaching Fauci-assistant Dr. David Morens how to erase emails? And how many thousands of them has she purged over the last several decades?  

It's a milestone episode! Number Eight Hundred. That calls for a celebration. Not only does Ricochet co-founder Peter Robinson join to host, but our dear pal Dr. Jay Bhattacharya is able to take a moment away from running both the NIH and CDC to talk about the downfall of Anthony Fauci and his team's work to restore public trust in America's leading public health and scientific institutions. With the disarming humility we've always known him for, Dr. Jay explains what he found most striking about Fauci's journal entries and evastions before Congress. The gang then pivots to what must be done to prevent a bureaucrat from acquiring such dictatorial powers and taxpayers from having to fund their own pandemic. Plus, Robinson, Hayward and Lileks wish the DNC luck in staving off the DSA; they find in our techno-innovators things to be hopeful for despite a generation that knew not the Soviets; they have a friendly debate over the triviality of pop-culture; and they say farewell to a departed Ricochet member.Sound from this week's open: Senator Rand Paul questions Anthony Fauci before the U.S. Senate Homeland Security and Governmental Affairs Committee.Closing Music: "Center of the Universe" by Markus Little, via MotionArrayBecome a supporter of this podcast: https://www.spreaker.com/podcast/the-ricochet-podcast--5817275/support.